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Chapter one
11. INTRODUCTION
Brief overview of prostate cancer
Prostate cancer (PCa) is a high-profile disease due to its incidence, the large
number of men dying yearly from the disease, the considerable debate
surrounding the benefit and risks of early detection, and the amount of
research currently ongoing in its detection, diagnosis and management. PCa
is now recognized as one of the most important medical problems facing the
male population.
The first chapter of this thesis outlines the current epidemiology, the natural
history, staging, diagnostic tools and management of prostate cancer.
1.1. Incidence
With ageing of the population, the development of the prostate specific
antigen (PSA) test, and the continuing decline in other common cancers such
as lung and stomach since the mid 1980s, prostate cancer has become the
most common cancer among men [Figure 1], accounting for about one in four
(24%) of all new male cancers diagnosed in the UK in 2008 [1].
There were 40,841 newly diagnosed PCa cases in the UK in 2009, compared
to 22,846 cases of lung cancer and 22,097 cases of colorectal cancer. The
cancer statistics in Europe [2] showed that there were 345,900 new cases of
prostate cancer diagnosed in 2006.
2Figure 1. Distribution of male cancer types in the UK in 2009 (data from
Cancer Research UK)
The burden of the disease largely occurs among older men, with very few
cases registered in men under 50 and more than 60% of cases occurring in
men over 70 years old. Incidence rates rise steeply with age, for men aged
55-59 the incidence rate is 155 per 100,000 men; reaching 510 per 100,000
at age 65-69, and by 75-79 the rate is almost five times higher at 751 per
100,000 [Figure 2]. [3]
3Figure 2. Numbers of new cases and age-specific incidence rates of
prostate cancer, UK 2009 (data from Cancer Research UK)
Latent carcinoma of the prostate is found in a large proportion of elderly men
with a clinically normal prostate. Autopsy studies have shown that between
15-40% of men aged 50 years and over have small, well differentiated
tumours within the peripheral zone of the prostate gland that never presented
clinically and would not otherwise have been detected. By the age of 80,
microscopically detected prostatic adenocarcinoma is present in 70-80% of
all men [4]. In another autopsy study [5], the authors found a 38.8%
prevalence of incidental prostate cancer with an increasing age-related
incidence, reaching 86.6% in the age group between 81 and 95 years.
41.1.1.Trends in prostate cancer incidence
Substantial increases in prostate cancer incidence have been reported in the
last 25 years with an average increase of 4% annually worldwide. From 1993
until 2008, the incident rates have increased by almost 56% with the
incidence rate of 62 per 100,000 men in 1993 rising to 98 per 100,000 in
2008 [Figure 3]. This increase was observed in the UK across all age groups,
but most markedly in men aged 55-64 years.
Figure 3. Increasing incidence of prostate cancer in Great Britain from
1993 to 2008 (data from Cancer Research UK)
Some of this increase is due to a real rise in incidence, since the rise in life
expectancy causes an increase in the number of men at risk. However, other
factors also contribute, namely greater awareness, improved diagnostic
techniques, increased reporting of small foci of cancer in pathology
specimens [6], as well as the rise in the number of transurethral resections of
5the prostate (TURP) performed in the 1980s and the substantial rise in PSA
testing in the 1990s [7].
The effect of PSA testing on incidence rates was most noticeable in the
United States population following the introduction of PSA screening in the
early 1990s [Figure 4].
Figure 4. Age-adjusted cancer incidence rates for men in the United
States. Noted the sharp increase in rate of prostate cancer detection in
early 1990s. The later decline in incidence may represent the effect of
screening anticipation as cases that were bound to present have
already been diagnosed at screening. (Data obtained from The National
Cancer Data Base report on prostate carcinoma, The American College
of Surgeons Commission on Cancer and the American Cancer Society
[8]).
61.1.2.Geographic variation in prostate cancer incidence
There is a 30-fold variation in prostate cancer incidence rates reported
between populations [Figure 5]. The highest reported rates are found in the
USA, where the age-standardized rates exceed 120 per 100,000 men. The
lowest rates are seen in Asian countries (less than 10 per 100,000 men) [1].
Figure 5. Prostate cancer incidence and mortality rates around the
world in 2006 (data from Cancer Research UK).
The large variation in reported incidence rates between countries is partially
due to the differences in detection. In Western countries, transurethral
resection of the prostate (TURP) is a common procedure carried out for the
treatment of obstructive symptoms. The prostatic chippings are routinely sent
for histological examination, and in up to 15% of cases, this reveals a small
unsuspected prostate cancer, which increases the detection rates [9].
7Moreover, the introduction of PSA screening in the USA, Australia and some
European countries in health check clinics led to inflation in the detection of
small asymptomatic tumours. It is noted that the low incidence rate in Japan
is expected to increase by three to four fold when US-based methods of
detection are employed. However, the rate will remain 50% lower than that
found in men of Japanese ancestry in the USA and 75% lower than that in
Caucasian American men. This suggests that both environmental and
genetic factors contribute to the variation in incidence rates between
countries.
1.2. Mortality
Prostate cancer is the second most common cause of cancer death in men,
after lung cancer, accounting for approximately 13% of male deaths from
cancer in the UK [1]. In Europe there were 87,400 reported deaths from
prostate cancer in 2006, with an estimated age-standardized mortality rate of
22.2 per 100,000 men [2]. Contrary to incidence rates, prostate cancer
mortality rates have remained stable in the UK over the last 10 years [Figure
6]. It is not known whether this stability is due to PSA screening and
detection of early cancer, to improved treatment or to changes in assigning a
cause of death. We are aware that many more men are diagnosed with
prostate cancer than die from it.
8Figure 6. Incidence rate and age-standardized mortality rate for prostate
cancer, Great Britain, 1975-2008 (Data from Cancer Research UK). Note
the stable mortality rate between 1975 and 2008 despite the dramatic
increase in incidence rate.
Data from the Surveillance, Epidemiology and End Result (SEER) program of
the National Cancer Institute (NCI) indicated that the 5 year overall survival
rate for patients with metastatic disease was 33%. In comparison, men with
regional stage disease (T3, T4, N1) had a 98% 5 year survival rate [10].
Overall survival rates for PCa, as opposed to mortality, have increased over
the last two decades. This is likely due to the lead time bias with the use of
PSA testing. Parker et al (2006) demonstrated a 26% 15 year survival benefit
from curative treatment compared with conservative management alone for
men age 55-59 years with intermediate or high aggressive tumour (Gleason
9score >7) [11]. The survival benefit is noted to be less for older patients and
for those with low aggressive (Gleason 6) tumours. Further discussion on the
rational of PCa treatment and its effect on mortality are described later in this
chapter.
1.3. Natural history of prostate cancer
The natural history of prostate cancer was described years before the advent
of PSA testing. The best documented details exist in the data compiled over
many years in centres where prostate cancer was treated conservatively. By
looking at what happened to men with conservatively managed PCa, we can
understand how the disease progresses when it is detectable clinically
without the effect of PSA lead-time bias, and left undisturbed until late in its
course.
The question that has always been raised by urologists is “How can we
distinguish between men who are likely to die from PCa and those with
indolent disease?” The first observation of deferred treatment was reported
by RW Barnes [12] in the late 1960s. He compiled data on patients between
1930 -1958. His inclusion criteria were: nodule palpable on digital rectal
examination, histologically confirmed PCa (by needle biopsy or
prostatectomy for BPH), and clinical follow up for between 10 to 15 years. His
results showed that at 10 years, 24% of patients died from other causes and
24% of patients died from prostate cancer. At 15 years 38% of patients died
from other causes compared to 32% deaths from prostate cancer. He
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concluded that competing medical co-morbidity is more likely to cause patient
death than prostate cancer.
In 2004, Johansson et al [13] published data on 223 men from Orebro,
Sweden, who had received deferred treatment for PCa. This cohort of
patients had been followed for an average observation period of 21 years.
The patients who had tumour progression were treated with hormone
manipulation if they were symptomatic. Most cancers had an indolent course
during the first 10 to 15 years. However, follow up from 15 to 20 years
showed substantial decrease in progression free survival from 45 to 36
percent and reduction in the prostate cancer specific survival rate from 78.7
to 54.4 percent.
Albertson et al [14], reported an analysis of data from the SEER
(Surveillance, Epidemiology and End Results) Trial. The study was designed
to estimate survival based on a competing risk analysis stratified by age at
diagnosis and Gleason score on histological examination from needle biopsy
specimens for men diagnosed as having clinically localised PCa and who
were managed conservatively. The study included 767 men diagnosed with
PCa between 1971 and 1984 and subsequently followed up for 20 years. The
authors showed that men with tumours of Gleason scores 6,7, and 8-10 had
a 18-30, 42-70, and 60-87 percent chance, respectively, of dying from the
disease within 15 years of diagnosis.
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Several points have emerged from PCa natural history studies:
1) Early stage, low grade disease can be treated successfully with
conservative management in older men with a good outcome of at
least 10 and perhaps 15 years of survival.
2) Aggressive prostate cancer results in high rate of mortality when left
untreated
3) Age and co-morbidity are important factors in making decisions about
treatment.
1.4. Prostate Specific Antigen
1.4.1.Introduction of PSA
PSA is a protein produced by normal prostate cells. This enzyme participates
in the dissolution of the seminal fluid coagulum and plays an important role in
fertility. The highest concentration of PSA is found in the seminal fluid, where
it was first discovered. Some PSA escapes the prostate and can be found in
the serum. PSA was first identified and purified in 1970s. However, its
widespread use in clinical urology did not occur until 1980s. The half-life of
PSA is about 2.2 to 3.2 days. Because of its relatively long half-life, a
minimum of 2-3 weeks is required for the serum PSA to reach its nadir
following radical prostatectomy, when it should be undetectable.
PSA testing is minimally invasive, simple and safe. Serum PSA elevation
may indicate the presence of prostatic disease (including prostate cancer,
benign prostatic hypertrophy, urinary retention and prostatitis) or result from
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prostate manipulation such as transrectal biopsy and prostatic massage.
Elevation of PSA above 4ng/mL carries a 22% probability of prostate cancer,
and a further increase  above 10ng/mL raises the cancer risk to 63% [15].
As PSA values rise with age, there is an agreed cut-off level for different age
groups [Table 1]. Although this is not universally accepted, as men may
harbor PCa despite low levels of serum PSA, the use of an age-specific
normal range for PSA values increases the positive predictive value of PSA
testing. The following table details the normal range of values according to
age.
Age group Normal PSA value
>60 PSA ≤3
60-69 PSA ≤4
>70 PSA ≤5
Table 1. Outlines normal age-specific PSA (data from Cancer Research
UK)
In a study of 1167 men aged 60 with PSA of less than 1 ng/ml [16], Lilja et al
found that they were unlikely to have clinically relevant prostate cancer (0.5%
risk of metastasis by age 85 and 0.2% risk of death from prostate cancer).
1.4.2. PSA modalities
A number of modalities have been proposed to enhance PSA usability such
as PSA velocity, PSA density, age-specific PSA and free/total PSA ratio.
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PSA velocity
This is defined as the change of PSA value over time; it enhanced the
specificity for prostate cancer detection from 42% to 96% when it was studied
over a 5 year period [17], compared to a single reading of PSA. In another
recent large scale study which involved 4,272 patients [18] and which
extended over a 10 year period, men with prostate cancer were found to
have significantly greater PSA velocity than those without cancer (0.39
versus 0.03).
PSA velocity as a predictor of tumour stage and grade remains controversial
[19, 20]. A more important and established role of PSA velocity is the follow
up of patients with prostate cancer who are either on active surveillance
strategy, hormone manipulation or post radical treatment [21].
PSA density
This is defined as the serum PSA level divided by the volume of the prostate.
It allows adjustments for the PSA component that arise from benign prostatic
hypertrophy which arises mainly in the transitional zone [22]. The clinical use
of PSA density has been debated. In a study done by Freedland et al [23] the
additional time and effort required to calculate PSA density was not justified
by the minimal improvement in predicting tumour stage, surgical margin and
biochemical recurrence after radical prostatectomy. However, more recent
studies have shown that PSA density may add additional prognostic value to
predict cancer progression. Tosoian et al, from John Hopkins Hospital,
considered PSA density as an important criterion for patients who opted for
an active surveillance strategy [24].
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Role of free/total PSA
This parameter has emerged after the discovery that PSA exists in a
complexed (bound) form with other proteins and free (unbound) form that can
be detected with immunoassays. Stenman et al [25] were the first to establish
that men with prostate cancer had more complexed PSA (cPSA) than free
PSA (fPSA), in contrast to men with benign prostatic hypertrophy, suggesting
that the assay of the complex and its proportion to total PSA immune-
reactivity can be used to differentiate between PSA elevations caused by
benign and malignant prostatic disease. A clinical study done in Egypt
showed that men with prostate cancer and a lower free/total PSA ratio had
higher Gleason scores than those with higher free/total PSA [26].
1.4.3.PSA screening
Screening to identify organ-confined prostate cancer has provoked much
public and scientific attention and there is intense debate about its role in
improving men’s health. The purpose of screening is to identify a group of
asymptomatic men with early stage, organ confined prostate cancer, which
would benefit from early radical intervention in terms of prolonged survival
and/or improved quality of life. To date, there is no evidence in the literature
that these benefits can be obtained by the establishment of mass screening
programs.
Two large studies [27, 28] – the US based Prostate, Lung, Colorectal, and
Ovarian (PLCO) cancer screening trial, and the European Randomized Study
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of Screening for Prostate Cancer (ERSPC)- present the most comprehensive
and up-to-date findings on PCa screening.
The PLCO trial recruited 76,693 men from 10 US centres. The screening
group consisted of 38,343 men and the control arm included 38,350 men.
Men in the screening group received annual PSA screening. The incidence of
death per 10,000 person-years was 2.0 in the screening group and 1.7 in the
control group with a rate ratio of 1.13 (95% CI, 0.75 – 1.70). These results
show that after an average of 7 years of follow-up, mortality did not
significantly differ between the screened and the control groups. The
contamination in this study selection is that although men the control group
were not actively screened, some patients received screening outside of the
study.
On the other hand, the ERSPC trial recruited 167,387 men from 7 European
centres into a PSA screening trial and showed about 20% reduction in the
risk of dying from PCa at 7 years. But this comes at a price, as to prevent 1
cancer death, 1400 men need to be screened in the age group 55-69 years
and 48 men need to be treated with all the side effects of treatment.
In conclusion, based on evidence from studies, young patients with long life
expectancy have the greatest benefits in PSA testing. However, if PSA is
recommended, the pros and cons must be stressed in the discussion,
including the anxiety generated by the screening process, as well as the
morbidity associated with treatment.
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1.4.4.Trans rectal Ultrasound biopsy
Since the initial description of the sextant prostate biopsies by Hodge, very
little changes were made until Stamey et al [29] extended the standard
biopsies to include the lateral areas of peripheral zones. However, even with
the extended biopsies, up to 30% of cancers can be missed. At present, most
urologists and radiologists use 12 systematic core biopsies including the
most lateral anterior horns of the peripheral zones. This increased the
detection rate for prostate cancer by 25% [30]. different researchers have
demonstrated that saturation biopsy techniques aimed at greatly increasing
the number of samples (more than 24 biopsies) and varying the distribution
of biopsy sites may provide a higher cancer detection rate up to 41% [31].
In a large systemic review of literature, Scattoni et al [32] conclude that it is
now reasonable to consider a sampling with 12 cores of the peripheral gland
as adequate even if limiting the number of cores to 12 in larger prostate is of
concern, and the risk of detecting insignificant tumour should not be
neglected. A more invasive saturation or template biopsies should be
preserved for repeat biopsies when clinically supecious cancer was not
diagnosed on the initial biopsy.
1.5. Anatomy of the prostate
The prostate gland [Figure 7] extends from the bladder base to the urogenital
diaphragm. It envelops the prostatic urethra and the ejaculatory ducts. It
measures approximately 4x3x2 cm. The anterior surface lies at the back of
the retropubic space and is connected to the pubic bone by the puboprostatic
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ligaments. The infero-lateral surface sits on the levator prostatae, a
component of levator ani. The posterior surface is in front of the rectum and
separated from it by the retrovesical fascia.
The prostatic urethra runs through the centre of the prostate gland and bends
anteriorly by approximately 35 degrees at the verumontanum, where the
ejaculatory ducts join the prostate.
Figure 7. Sagittal section of the anatomy of the male pelvis showing the
location and relationship of the prostate and seminal vesicles (image
obtained from the introduction to urology course, Sheffield).
The prostate can be divided into 4 zonal components [33] excluding the
urethra and periurethral glands [Figure 8]. These are as follows:
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1- The anterior non-glandular fibromuscular stroma, which contains
smooth muscle, helps to squeeze secretions during ejaculation. It
merges with the fibromuscular tissue of the urogenital diaphragm.
2- The transition zone consists of 2 independent pear shaped lobes
situated laterally on either side of the prostatic urethra together with
periurethral glands. This is the zone where benign prostatic
hypertrophy (BPH) occurs.
3- The central zone surrounds the transitional zone posteriorly and
encloses the ejaculatory ducts. It is the zone most commonly affected
by inflammatory processes (e.g. prostatitis). In benign prostatic
hyperplasia, the transitional zone and periurethral glands enlarge
considerably compressing the central zone to form a thin layer, the so-
called surgical pseudocapsule.
4- The peripheral zone is the most posterolateral glandular component of
the prostate. The ratio of peripheral zone to central gland tissue
gradually decreases from the apex to the base of the gland. The
peripheral zone can be compressed and distorted by BPH and it is the
site of the majority of prostate cancers.
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Figure 8. Axial and sagittal views of the prostate showing normal zonal
anatomy (obtained from www.aboutcancer.com/prostate anatomy).
The prostate capsule is a fibromuscular layer, most prominent along the base
and posterior portions of the lateral borders. It consists of an outer layer,
termed the lateral pelvic fascia and an inner layer, the so called prostatic
fascia which is inseparable from the prostatic stroma [34]. At the prostatic
apex and bladder neck regions, the capsule is lacking and the prostatic
connective tissue is inseparable from the surrounding extraprostatic
connective tissue [35].
The prostatic capsule is separated from the pelvic muscles by loose
connective and adipose tissue containing the periprostatic venous plexus,
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arteries, nerves and lymphatics. At the posterolateral aspects of the prostate
these structures form the neurovascular bundles containing cavernous nerve
fibers that are important for erectile function. At the apex of the prostate,
benign prostatic glands are mixed with skeletal muscle bundles of the
urogenital diaphragm. This makes assessment of apical tumour extension
more difficult.
1.5.1.Prostate arterial supply and venous drainage
The inferior vesical artery supplies the prostate via its urethral and capsular
branches. The urethral arteries enter the prostate at the posterolateral
vesico-prostatic junction and supply the bladder neck and periurethral zone
of the prostate. The capsular branches run in the lateral pelvic fascia
posterolateral to the gland along the pelvic sidewall, supplying the outer part
of the prostate. The inferior vesical artery also provides branches to the
seminal vesicles and the bladder base.
Prostatic veins drain into Santorini’s plexus. The deep dorsal vein leaves the
penis under Buck’s fascia between the corpora cavernosa and penetrates the
urogenital diaphragm, dividing into the superficial branch and the right and
left lateral venous plexuses [36]. The superficial branch overlies the bladder
neck and prostate penetrating through the middle of the puboprostatic
ligaments. The lateral venous plexuses are concealed by the prostate and
endopelvic fascia travelling posterolaterally and communicate with the
pudendal, obturator and vesical plexuses. Also some branches from the
lateral plexuses penetrate the pelvic sidewall to communicate with the
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internal pudendal vein. After interconnection with other veins and plexuses,
the lateral plexuses form the inferior vesical vein which drains into the
internal iliac vein.
1.5.2.Prostatic innervation:
The innervation of the prostate comes from the pelvic plexus, which is formed
by parasympathetic, visceral fibers arising from the sacral centre (S2 to S4)
and sympathetic fibers from the thoracolumbar centre (T12 to L2). The
prostatic nerves travel outside the prostate capsule and Denonvillier’s fascia
and enter the prostate by perforating the prostatic capsule. The
neurovascular bundles are located in the lateral pelvic fascia between the
prostatic and levator fascia. They continue laterally to the prostate and pierce
the urogenital diaphragm to enter the corpora cavernosa. Although nerves
within the bundles are very small, they can be identified intraoperatively by
using the capsular vessels as a landmark.
1.6. Prostate histology:
The prostate gland consists of stromal elements (smooth muscle cells,
fibroblasts and endothelial cells), epithelial elements (secretory cells, basal
cells and neuroendocrine cells) and urethral cells which line the urethra
[Figure 9]. Secretory cells are located along the glandular lumen and stain for
PSA. The basal cells, which consist of low cuboidal epithelium and columnar
mucus secreting cells, separate the secretory cells from the basement
membrane and neuroendocrine cells which are irregularly distributed.
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Figure 9. Haematoxylin and eosin section of normal prostate tissue at
low magnification (X200), showing glandular units (stained blue/purple)
surrounded by stroma elements rich in smooth muscle (stained pink).
1.7. Physiology of prostate:
The main role of the prostate is to produce fluid, which accounts for up to
30% of the semen volume. It aids sperm motility and provides nourishment.
Prostatic fluid is a thin, milky alkaline liquid containing citric acid, calcium,
zinc, acid phosphatase and fibrinolysin as well as PSA.
1.8. Pathology of Prostate Cancer
Adenocarcinomas account for 95% of prostate cancers and in most of cases
they arise from the peripheral zone. In the remaining cases, tumours are
located in the transitional zone either in a periurethral or anterior location.
Adenocarcinoma of the prostate is multifocal in more than 85% of cases [37].
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In the majority of these multifocal tumours, the additional foci of tumour are
small and clinically insignificant.
Other histologic variants of prostatic carcinoma include Signet ring cell
carcinoma, adenosquamous carcinoma, squamous cell carcinoma, basaloid
and adenoid cystic carcinoma, transitional cell carcinoma, small cell
carcinoma, sarcomatoid carcinoma, lymphoepithelioma-like carcinoma and
undifferentiated carcinoma. Approximately 4% of prostate cancer cases have
transitional cell morphology and are thought to have arisen from the urothelial
lining of the prostatic urethra. Small cell carcinoma is another type of prostate
cancer formed from the hormone producing (neuroendocrine) cells of the
prostate. Neuroendocrine differentiation of tumour is more prominent during
hormone manipulation. However, a recent study did not support that
assumption but suggested that androgen-independent neuroendocrine cells
existed before therapy [38].
1.8.1.Prostatic Intraepithelial Neoplasia (PIN)
PIN was first described by Bostwick and Brawer in 1987 [39]. It was identified
as a precursor lesion to prostatic carcinoma. It refers to the pre-cancerous
end of a morphologic spectrum involving cellular proliferation within prostatic
ducts, ductules and acini [39]. The importance of high grade PIN (HGPIN) is
its potential to invade and breach the basal membrane, thereby transforming
into invasive cancer. HGPIN identifies patients who are at risk of either
having a co-existing cancer or subsequently developing one [40].
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The incidence of HGPIN ranges between 0.7-20% in prostatic needle
biopsies with an average of 8.7% [40].
When HGPIN is present in the biopsy specimen, the pathologist should
carefully search the tissue for evidence of invasive carcinoma, as studies of
autopsy and radical prostatectomy specimens have shown coexisting
prostate cancer in 63-94% of HGPIN cases [41]. The likelihood of identifying
coexisting prostate cancer in patients with HGPIN on the first biopsy has
increased over the years mainly due to more rigorous biopsy techniques and
the use of transrectal ultrasound guidance for directing biopsies [40].
HGPIN has been established to be a precursor of prostate cancer with 33-
50% of patients having prostate cancer detected on repeated biopsy [42].
However, the most recent study showed a trend toward decreasing incidence
of subsequent cancer, mainly due to better detection of cancer on the initial
biopsy [40].
No consensus has been reached about the optimal follow-up time for patients
with HGPIN. Some studies have strongly advised repeated prostate biopsy
for all patients with HGPIN to identify those with prostate cancer [43],
regardless of their PSA findings [44], especially in the first 3 years after
diagnosing HGPIN, supporting the concept that HGPIN is a precursor of
prostate cancer. A study from John Hopkins Hospital [45] also showed that
repeated biopsy identified cancer in 32.2% of men with HGPIN. The greater
the number of cores affected by HGPIN, the higher the risk of cancer being
detected on repeated biopsies (75% risk of cancer in cases with >3 biopsy
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cores involved with HGPIN). By contrast, Epstein et al did not recommend
routine repeat biopsies within the first year following a diagnosis of HGPIN,
since they found that the rate of subsequent prostate cancer detection is
similar to that reported following a benign diagnosis on needle biopsy [46].
Other experts have taken different approaches in more recent studies. As the
risk of cancer is related to the proportion of the biopsy cores replaced by
HGPIN, only multifocal HGPIN warrants re-biopsy, whereas unifocal HGPIN
can be managed expectantly [41] with PSA or PSA velocity measurements
[47].
1.8.2.Atypical and suspicious small acinar proliferations (ASAP)
ASAP was first described by Bostwick et al [48] as the presence of
suspicious glands with insufficient cytological or architectural atypia for a
definite diagnosis of cancer. Therefore, it is not a specific diagnosis, but an
indication of diagnostic uncertainly. Histological appearances are similar to
prostate adenocarcinoma but have smaller foci with fewer acini involved, less
nuclear enlargement and hyperchromasia, absence of mitosis and lack of
infiltration [49] of normal surrounding tissues.
The incidence of ASAP, in a study involving over 1000 prostatic biopsies,
was found to be around 4.8% [50] ranging between 1.5-9% for different
series [51]. The presence of ASAP on prostate biopsy is a strong predictor of
cancer and is much more important than HGPIN. The subsequent prostate
cancer detection rate after a diagnosis of ASAP is around 50-55% [51, 52],
which is significantly higher than following HGPIN or benign biopsy.
Therefore, early (after 3-4 months) repeat biopsies are strongly indicated
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after a diagnosis of ASAP [53] and should not be limited to the site of ASAP
findings, but extended to the whole gland [52].
Urologists should be aware of ASAP and recognize its significance relative to
HGPIN, and arrange appropriately timed follow up and re-biopsy.
1.8.3.Grading system:
The most commonly used system for classifying histologic characteristics of
prostate cancer is the Gleason score described by Gleason et al in 1974 [54].
It is based on the glandular pattern of the tumour. Both the predominant and
the second most prevalent architectural pattern are assigned a grade from 1
to 5 (1 being the most differentiated and 5 being the least differentiated).
Therefore, Gleason score 7a (3+4) has better prognosis that Gleason score
7b (4+3). It was concluded that a two tier Gleason system has greater
discriminating power in predicting prognosis in patients with prostatic
adenocarcinoma. In cases in which only a single pattern is present, the
primary grade is doubled to derive the Gleason score [Figure 10].
Over the last decade, there has been a decline in the reported incidence of
low-grade prostate cancers as a result of Gleason score reclassification
(grade shift). This reclassification resulted in apparent improvement in clinical
outcomes, since transferring the more aggressive tumours from the good
prognostic group to the bad prognostic group, the prognostics of both groups
improve. This finding reflects a statistical artifact known as the Will Rogers
phenomenon.
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Figure 10. Gleason grading system for prostate cancer. Grades 1 to 5
are defined as detailed below:
Grade 1 tumours consist of small, uniform glands with minimal nuclear
changes.
Grade 2 tumours have medium sized acini, still separated by stromal
tissue.
Grade 3 tumours show marked variation in glandular size and
organization, and infiltrating stroma.
Grade 4 tumours show marked cytologic atypia and extensive
infiltration.
Grade 5 tumours are characterized by sheets of undifferentiated cancer
cells.
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1.8.4.Staging of prostate cancer:
Prostate cancer can spread locally as well as metastatically. Organ confined
disease is staged as either pt1 which represents a clinically unapparent
tumour diagnosed on histologic findings from transurethral resection or
needle biopsy, or as pt2 disease, with tumour involving the prostate gland but
not extending to its capsule.
Extraprostatic extension is the term recommended by Epstein et al [55] when
the tumour extends beyond the normal confines of the prostate gland. This
represents stage pt3 disease. Stage pt3a is considered to be present when
cancer only extends out of the prostatic capsule into the periprostatic soft
tissue and fat or when there is invasion of the neurovascular bundles.
Assessment of extraprostatic extension at the apex is more difficult. Some
pathologists believe that it cannot be assessed at this site. Others describe
apical extraprostatic extension if tumour is seen beyond the level of normal
prostatic acini.
Stage pt3b disease is defined as tumour infiltrating the seminal vesicles. It
occurs either through tumour penetration of the capsule at the base of the
gland into the peri-seminal space and eventually into the seminal vesicles, or
less commonly through direct spread via the ejaculatory ducts or as
discontinuous metastases. In a study involving 763 patients with prostate
cancer, it was found that seminal vesicle involvement is rare (1.2% of
patients) in the absence of tumour at the prostatic base [56]. Further
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involvement of adjacent organs such as bladder and rectum is considered as
stage pt4 disease.
The most frequent sites of metastatic prostate cancer are lymph nodes and
bone. The primary lymphatic vessels from the prostate gland drain into the
regional lymph nodes of the pelvis. These include the internal iliac
(hypogastric), sacral, peri-vesical, obturator, and external iliac lymph node
groups. The last 2 sites are considered as the first line of lymphatic spread
and are commonly dissected during radical prostatectomy. Occasionally
metastases go beyond regional lymph nodes and involve distant lymph
nodes including deep and superficial inguinal, common iliac, retroperitoneal
(aortocaval nodes), supraclavicular, cervical and scalene nodes.
Bony metastases can occur early without significant lymphadenopathy. Two
theories have been proposed for spread: either direct spread through the
lymphatics and venous spaces into the lower lumbar spine [57]; or the seed-
and-soil theory which believes that tissue factors must be present to allow
preferential tumour cell growth in certain tissues, such as the bone [58, 59].
Bony metastases from prostate cancer are commonly osteoblastic (unlike
other types of cancers), but osteoclastic lesions can also be found. The
underlying mechanisms for prostate cancer-induced osteoblastic activity are
poorly understood despite recent studies on the cellular and molecular
interactions between prostate cancer and bone cells. A study done by
Nadiminty et al suggested that over-expression of PSA may be involved in
bone remodeling and induction of osteoblastic differentiation [60].
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Following in frequency after lymph nodes and bone, the next most common
regions of metastatic spread are lungs, bladder, liver, adrenal glands and
testes.
There have been several modifications to the staging system for prostate
cancer. The currently used staging system is the 2002 modified TNM system
(T = tumour, N = node, M = metastasis) [61]. The various stages of disease
are as follows:
 T - Primary tumour
 TX - Primary tumour cannot be assessed
 T0 - No evidence of primary tumor
 T1 - Clinically unapparent tumour not palpable or visible by imaging
 T1a - Tumour incidental histologic finding in less than or equal to 5% of
tissue resected
 T1b - Tumour incidental histologic finding in greater than 5% of tissue
resected
 T1c - Tumour identified by needle biopsy (because of elevated PSA level);
tumours found in 1 or both lobes by needle biopsy but not palpable or
reliably visible by imaging
 T2 - Tumour confined within prostate
 T2a - Tumour involving less than half a lobe
 T2b - Tumour involving less than or equal to 1 lobe
 T2c - Tumour involving both lobes
 T3 - Tumour extending through the prostatic capsule; no invasion into the
prostatic apex or into, but not beyond, the prostatic capsule
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 T3a - Extraprostatic extension (unilateral or bilateral)
 T3b - Tumour invading seminal vesicle(s)
 T4 - Tumour fixed or invading adjacent structures other than seminal
vesicles (e.g., bladder neck, external sphincter, rectum, levator muscles,
pelvic wall)
 NX - Regional lymph nodes (cannot be assessed)
 N0 - No regional lymph node metastasis
 N1 - Metastasis in a single lymph node, 2 cm or less in greatest dimension
 N2 - Metastasis in a single lymph node, more than 2cm but not more than
5 cm in greatest dimension, or multiple lymph nodes, none more than 5 cm
in greatest dimension
 N3 - Metastasis in a lymph node more than 5 cm in greatest dimension
 Mx - Presence of distant metastasis cannot be assessed
 M0 - No distant metastasis
 M1 - Distant metastasis
 M1a - Non regional lymph nodes
 M1b - Bone
 M1c – other sites
1.9. Radical prostatectomy
1.9.1.Preoperative clinical staging and prediction
Staging aims to distinguish between localised, locally advanced and
metastatic disease in order to decide the optimal treatment pathway and to
predict prognosis. The primary assessment of the extent of prostate
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carcinoma is made by digital rectal examination (DRE) and serum prostate
specific antigen (PSA) measurement. However, prostate cancer detection
rate by DRE alone is very poor (2.5%) particularly in patients with low PSA
values, as reported by Schroder et al from the Rotterdam section of the
European Randomized Study of Screening for Prostate Cancer [62]. In
addition, there has been no documented correlation between DRE and
pathological stage [63]. DRE often underestimates the extent of tumour
especially for T3 disease. With a positive DRE, the positive predictive value
for cancer detection is significantly dependent on PSA value [64] [Table 2].
However, PSA has a low cancer specificity and no ability in isolation to
predict the pathological staging due to the overlap in PSA levels between
different tumour stages [65].
PSA ng/mL Positive Predictive Value for Cancer
0-1 2.8-5%
1-2.5 10.5-14%
2.5-4 22-30%
4-10 41%
>10 69%
Table 2. PPV of PSA for cancer detection in patients with positive
findings on DRE. The higher the PSA, the more likely that its elevation
is due to cancer. (European Association of Urology Guidelines, 2011)
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Partin at al [66] combined independent variables including DRE staging, PSA
and Gleason score on prostatic biopsy to produce a statistical prediction of
the final pathological stage. This has been widely used by urologists to guide
patient management and to predict the outcome of radical prostatectomy. For
example, a patient with non palpable disease and a PSA value between 4.1
and 6, with Gleason 6 on prostate biopsy, has an 80% chance of having
organ confined disease compared to 46% if the Gleason score was 8-10.
Various electronic and online applications have been put in place to facilitate
the use of Partin’s table in clinical practice.
The good predictive accuracy of Partin’s table has been confirmed by other
authors who have reported area under the curve (AUC) values of 0.784,
0.728, 0.791 and 0.799 for organ-confined tumour, extracapsular extension
(ECE), seminal vesicle involvement (SVI) and lymph node involvement
respectively [67]. Another predicting nomogram was produced by Kattan et al
[68]. This was developed from data on a group of 983 men with clinically
localised prostate cancer with the intention of predicting 5 year disease
recurrence rate for patients with clinically localised PCa undergoing radical
prostatectomy. It uses preoperative clinical factors including preoperative
PSA, biopsy derived Gleason score and clinical stage [Figure 11].
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Figure 11. Kattan’s nomogram for predicting prostate cancer
recurrence after radical prostatectomy. Adapted from Kattan MW et al.
A preoperative nomogram for disease recurrence following radical
prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:768.
D’Amico et al established a prostate cancer recurrence risk stratification
scheme for patients undergoing radical prostatectomy and defined risk as
low, intermediate or high [69] [Table 3].
Low risk
PSA ≤ 10 ng/mL, and Gleason score ≤ 6, and clinical stage
T1c or T2a
Intermediate risk PSA  10 - 20 ng/mL, or Gleason score = 7, or T2b
High risk PSA > 20 ng/mL, or Gleason score ≥ 8, or T2c
Table 3. Prostate cancer risk stratification (from D’Amico et al [70])
Low-risk patients are most likely to remain disease-free following local
therapy, whereas high-risk patients have an increased risk of subsequent
biochemical failure and clinical progression. D’Amico’s risk stratification has
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been widely used to counsel patients and help decide between active
surveillance and active treatment. Low risk cancers generally have slow,
often clinically insignificant progression with these patients more likely to die
with the disease rather from it.
1.9.2.Anatomic open radical retropubic prostatectomy (nerve
sparing procedure)
 The procedure is done through a midline, extraperitoneal, lower
abdominal incision.
 Pelvic lymph node dissection is performed if indicated. The advantage
of pelvic lymphadenectomy (PLND) during radical prostatectomy is to
achieve more accurate staging, as it may influence decision-making
with respect to adjuvant therapy. But this is at a cost of increase
surgical morbidity and the risk of lymphoedema. The EAU guidelines
2011 reported that in D’Amico’s low risk patient group, pelvic lymph
node dissection is not necessary as the risk of positive lymph nodes
does not exceed 7%. However, it should be performed in intermediate
and high risk localised PCa. If PLND is undertaken, an extended
approach should be performed to include the obturator and external
iliac nodes as limited PLND (obturator nodes only) may miss at least
half of the nodes involved.
 The endopelvic fascia is incised where it reflects over the pelvic
sidewall and the incision is extended toward the puboprostatic
ligament and the levator ani muscular fibers are released from the
lateral surface of the prostate down to the apex
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 The puboprostatic ligaments are divided to expose the junction
between the prostatic apex and the anterior surface of the dorsal vein
complex.
 The dorsal vein complex is divided. The precise point of division is
important to ensure a negative margin at the apex, good urinary
continence whilst avoiding blunt trauma to the neurovascular bundles.
 The prostatourethral junction is then well visualized. The urethra is
transected as close to the apex as possible.
 The neurovascular bundle travels between the two layers of lateral
pelvic fascia, the levator fascia and the prostatic fascia. To preserve
the neurovascular bundle, the superficial layer of lateral pelvic fascia is
released from the bladder neck, where it is thickest, and extended
toward the apex of the prostate. The neurovascular bundle is then
identified and released laterally and posteriorly from the prostatic apex
to the midpoint of the prostate.
It has been reported [71] that the prediction of extraprostatic tumour
extension (EPE) in the region of the neurovascular bundle (NVB) is
greater than 10%, if 2 or more of the following are present:
o PSA >10ng/ml
o Gleason score >6
o Average % of biopsy core involved >20%
o % of cores with tumour >33%
o Positive DRE
Side specific
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Therefore, excision of the neurovascular bundle is considered if any of
the following occurs:
o Pre-operative factors:
 Prediction of extra-prostatic extension based on the
above features, Partin’s table, and/or suspicion of ECE
on prostate MR imaging.
 Patient’s desire to maintain sexual function.
 Palpable apical lesion, high probability of capsular
penetration (Partin’s table).
o Intra-operatively:
 Induration in lateral fascia
 Fixation of neurovascular bundle to prostate
 Inadequate tissue over lesion after prostate removal
(delayed excision)
 Once the neurovascular bundle is freed, the prostate is mobilized to its
midpoint, and the attachment between the Denonvilliers fascia and the
rectum is divided up to the tip of seminal vesicles.
 Once the prostate is freed completely, the bladder neck is incised
anteriorly at the prostatovesicular junction. The arterial branches from
the inferior vesical artery to the prostate are ligated and divided. The
seminal vesicles are freed from the posterior bladder wall which is
then divided at the bladder neck.
 The prostate and the seminal vesicle specimen is removed and
inspected for area of possible positive margins
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 The bladder neck is reconstructed, sutured to the urethra, and a Foley
catheter is placed.
1.9.3.Rationale for radical prostatectomy
In organ confined disease:
Radical prostatectomy is one of the recommended treatments for patients
with stage T1 and T2 prostate cancer and a life expectancy of more than ten
years. The prognosis is very good when the tumour is confined to the
prostate.
In 2005, the Scandinavian Prostate Cancer Group (SPCG) [72] reported the
results of a randomized control trial comparing radical prostatectomy with
watchful waiting, in the management of early prostate cancer. They found
that patients who were treated with radical prostatectomy had lower rates of
prostate-cancer death, distant metastasis and local regression. These
differences were mainly noticeable at ten years follow up with an absolute
risk reduction of 5.3%, 10.2% and 25.1% for prostate-cancer death,
metastasis and local regression respectively. The benefit of radical
prostatectomy in reducing death from prostate cancer was greater in men
aged less than 65 years. An update paper from the same group in 2011
reporting 15 years follow-up results [73], showed a cumulative incidence of
death from prostate cancer at 15 years of 14.6% and 20.7% for surgery
versus watchful waiting. The survival benefit was also noticed among men
with low-risk disease and was confined to men younger than 65 years of age.
The number needed to treat (NNT) to avert one death was 15 overall and 7
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for men younger than 65 years. Among men who underwent radical
retropubic prostatectomy (RRP), those with extracapsular invasion had a risk
of death from prostate cancer that was 7 times greater than those without.
The paper concludes that radical prostatectomy was associated with a
reduction in the rate of death from prostate cancer and that men with
extracapsular tumor growth may benefit from adjuvant local or systemic
treatment.
The outcome of radical prostatectomy has been studied extensively in
Europe and the USA. Most authors looked at follow up cancer specific and
overall survival rates for at least 10 years. Table 4 summarizes some of the
important studies.
Study No of
Pts
PSA Free
Survival %
Metastatic Free
Survival %
Cancer specific
survival %
Overall
Survival %
Gerber
1997 [74]
245 32 57
Hull 2002
[75]
1000 75 84 98
Ward
2005 [76]
841 43 73 90 76
Table 4. List of foremost studies looking at outcome following radical
prostatectomy
Radical prostatectomy treatment modality was also compared to radical
radiotherapy for localised prostate cancer. Kupelian et al [77] reviewed 787
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patients who were treated with surgery alone or radiotherapy alone, and
found a 5 year PSA relapse-free survival rate of 37% and 26% respectively,
for high risk patients ( PSA>10.0 or Gleason score >7) signifying a definite
advantage of surgery, if negative margins were achieved. However, for low
risk cases, there was no difference in outcome between radiotherapy and
prostatectomy over 5 to 7 years follow up [77, 78].
Unexpectantly, The Prostate Cancer Intervention versus Observation Trial
(PIVOT) study have been published in the New England Journal of Medicine
in July 2012 [79]. The trial enrolled 731 men with localised prostate cancer
between November 1994 and January 2002. Men were randomly assigned to
either be treated with a radical prostatectomy (RP) or observation. All
patients were followed until January 2010. Among men with localised
prostate cancer detected during the early era of PSA testing, radical
prostatectomy did not significantly reduce all-cause or prostate-cancer
mortality, as compared with observation, through at least 12 years of follow-
up.
In locally advanced prostate cancer:
Radical prostatectomy for T3 disease often results in incomplete tumour
excision, leading to higher morbidity and higher risk of recurrence compared
to patients with organ confined disease. Therefore, surgical treatment of
clinical stage T3 prostate cancer has been traditionally discouraged.
In recent years, interest in surgery for locally advanced prostate cancer has
grown. Clinical over-staging of PCa is relatively frequent and occurs in 23.5%
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of cases. These patients would be disadvantaged if their cancers were
considered as locally advanced disease and managed with other treatment
modalities. Hsu et al [80] showed, in a study involved 235 patients with
clinically T3 disease, a similarly good biochemical and clinical outcome after
surgery for patients with T3 disease and negative margins compared with T2
disease. However, patients with positive margins or positive lymph nodes
may require adjuvant or salvage radiotherapy or hormone therapy [81].
According to the guidelines of the European Association of Urology (EAU),
radical prostatectomy is an accepted option in selected patients with limited
T3a disease, Gleason score of ≤ 8, PSA < 20ng/mL and a life expectancy of
more than 10 years [64]. If radical prostatectomy is performed, a non-nerve
sparing approach and an extended pelvic lymphadenopathy should be
performed.
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1.9.4.Complications of radical prostatectomy:
Complications of radical prostatectomy according to EAU guidelines [64] are
listed in the table below:
Complication Incidence (%)
Peri-operative death 0.0-2.1
Major bleeding 1.0-11.5
Rectal injury 0.0-8.3
Pulmonary embolism 0.8-7.7
Lymphocoele 1.0-3.0
Urine leak, fistula 0.3-15.4
Slight stress incontinence 4.0-50.0
Severe stress incontinence 0.0-15.4
Impotence 29.0-100.0
Bladder neck obstruction 0.5-14.6
Ureteral obstruction 0.0-0.7
Urethral stricture 2.0-9.0
Deep venous thrombosis 0.0-8.3
Table 5. Complications of radical prostatectomy (European Association
of Urology guidelines, 2007)
The most common complications are bladder neck stenosis due to
anastomotic stricture, urinary incontinence and impotence. Factors that may
contribute to the development of an anastomotic stricture include previous
transurethral resection of prostate, intraoperative blood loss and urinary
extravasation at the anastomotic site. Stricture can be treated effectively with
simple dilatation or cold knife incision.
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Urinary incontinence remains the most troubling side effects of radical
prostatectomy. It is usually secondary to intrinsic sphincter deficiency seen in
older men, or damage to the smooth musculature of the urethra by deep
suturing the anastomosis or injuring the neurovascular bundles. Preservation
of the neurovascular bundles and selecting younger patients can play a role
in decreasing the incidence of incontinence. Improvement in incontinence
can occur up to 2 years post-surgery, but most commonly within the first year
post operatively. Erectile dysfunction after radical prostatectomy is common.
Predictive factors for recovery of potency are patient age, preoperative
erectile function and the extent of neurovascular bundle preservation.
1.9.5.Radical prostatectomy with positive surgical margins:
A positive surgical margin is defined as the presence of tumour at the inked
surface of the resected specimen. It is classified into extraprostatic and
intraprostatic. An extraprostatic positive margin is when cancer is cut through
after it has escaped the confines of the prostate i.e. cancer extends through
the ‘capsule’ into fat. Whereas, intraprostatic positive margin is when cancer
is cut through inside the glandular area of the prostate, therefore, the capsule
and fat are missing from the specimen [82].
There are 3 major causes of margin positivity: 1) poor specimen handling
leads to artificial positivity, 2) capsular incision and transection of
intraprostatic tumour intraoperatively, 3) inability to excise extraprostatic
tumour. The most common site of margin positivity is the apex, followed by
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the lateral and posterior regions and then the anterior aspect and bladder
neck.
Positive surgical margins are found to be an independent predictor of disease
progression after radical prostatectomy. Epstein et al reported 10 years
biochemical free survival of 79% in negative margin patients, versus 55% in
positive margin following radical prostatectomy [83]. However, two factors in
margin positivity affect tumour progression [35]. Firstly, the locations of the
positive margins, as apical margins do not correlate independently with
tumour progression, in contrast to bladder neck margin positivity. Secondly,
the degree of margin positivity, with extensive or multifocal positive margins
carrying a higher risk of tumour progression than solitary and focal positive
margins.
Management of positive surgical margins is still controversial. Some
urologists support the active surveillance strategy, as a good proportion of
patients with positive surgical margins have long term survival and a
reasonable disease-free progression rate [84]. On the other hand several
authors [85, 86] have suggested immediate adjuvant treatment with
radiotherapy in patients with positive margins, as this was found to improve
PSA-free survival and reduce local progression compared with a watchful
waiting strategy. The RADICALS trial is attempting to answer this question.
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1.10. Pathology reporting of radical
prostatectomy specimens
EAU guidelines in 2011 provide recommendations for Pathologists with
respect to processing and reporting radical prostatectomy specimens and
advise them to follow a standardized checklist. The specimen should be
totally embedded either by conventional (quadrant sectioning) or by whole-
mount sectioning (preferred). Then the entire surface of RP specimen should
be inked before cutting to allow assessment of surgical margin status. The
apex should be separately examined.
The pathologist should report the histological type and Gleason grade
including the primary and secondary grade. Reporting the percentage of
prostatic tissue involved is also preferred. Pathology staging should evaluate
the presence of extraprostatic extension at any specific site, the presence of
seminal vesicle invasion, the presence of lymph node metastases, including
the number of involved nodes. Surgical margin involvement should be
recorded if present and whether there is extra or intra-prostatic invasion.
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CHAPTER 2
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2. IMAGING OF PROSTATE CANCER
Patients who are clinically suitable for radical treatment are considered for
radiological imaging to enhance the sensitivity and specificity of the predictive
nomograms, to locate the cancer foci, and to exclude extracapsular
extension, seminal vesicle involvement or lymphadenopathy.
2.2. Trans-rectal ultrasound scanning (TRUS)
Before the introduction of TRUS, transabdominal ultrasonography was used
to detect and stage prostate cancer, with some overlap between the findings
in benign and malignant disease [87].
Prostate imaging with endorectal sonography was first described in 1968 by
Watanabe and colleagues [88]. The technique did not gain popularity until the
late 1980s, when the development of PSA testing increased the need for
TRUS biopsy. Initially, TRUS concentrated on the ultrasonic appearances of
prostate abnormalities such as benign prostatic hyperplasia (BPH),
carcinoma of the prostate, prostatitis, prostatic abscess, and prostatic calculi.
Since the evolution of end-firing probes, TRUS has mainly been used to
guide and monitor the entire process of needle prostatic biopsy.
Kuligowska et al reported low TRUS detection rates for malignancy, even
when coupled with colour Doppler US, with typical values of 57% sensitivity,
61% specificity, 44% PPV, 73% NPV and 60% accuracy [89]. In this and
other studies, more than half of prostate cancers were isoechoic with respect
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to surrounding tissues and were missed at gray-scale and colour Doppler
US. Moreover, benign hyperplasia may appear as a hypoechoic nodule
similar to PCa appearance [90].These results make TRUS an inadequate tool
for PCa screening and diagnosis, therefore targeted biopsy should always be
accompanied by complete standardized biopsy sampling.
With regard to staging, the specificity of TRUS alone for staging locally
advanced disease (T3) was only 25.3%, with sensitivity, PPV and NPV of
80.2%, 47.1% and 60.7% respectively [91]. With known poor staging
accuracy rate and operator dependence, TRUS is not recommended as a
staging method but still plays a major role in accurately sampling a wide-area
of prostatic tissue.
2.3. Computer Tomography (CT)
CT has been employed in newly diagnosed PCa mainly for radiotherapy
planning and assessing lymph node metastasis and has an accuracy rate of
about 70%. However, due to its low diagnostic staging accuracy of 24% for
extraprostatic extension [92], CT lacks the precision needed to evaluate local
spread, and newer, more accurate imaging modalities should be used to
decide whether or not to proceed to radical prostatectomy.
2.4. Positron emission tomography (PET)
PET studies have been introduced for identifying and localizing prostate
cancer. It was found that other prostatic disorders can accumulate choline
similar to prostate cancer lesions. PET/CT has been shown to have a high
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false negative rate, with a sensitivity of 66% and negative predictive value of
55%, which precludes its use for prostate cancer screening, detection or
staging [93].
2.5. Evolution of Magnetic Resonance Imaging
(MRI):
The first successful nuclear magnetic resonance (NMR) experiment was
made in 1946 independently by two scientists in the United States (Felix
Bloch and Edward Purcell). It was not until the early 1970s that magnetic field
gradients were introduced enabling the development of MR imaging. In 1977
the first human body images were obtained by Damadian, using a prototype
superconducting magnet.
MRI has particular advantages over CT in that it uses non-ionising radiation,
and has high soft tissue resolution and discrimination in any imaging plane. It
also provides both morphological and functional information.
MRI of the prostate appears to be the best imaging modality for identifying
locally advanced disease [94]. This is due to its excellent soft tissue contrast
which allows depiction of the prostate gland zonal anatomy [Figures 12, 13],
seminal vesicles [Figure 14] and prostate margins and its relationship to
surrounding structures in the pelvis.
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Figure 12. Normal prostate anatomy in a young man, detailing
prominent peripheral zones (PZ) and small central gland (CG).
Figure 13. Benign prostatic hypertrophy involving the central gland and
compressing the peripheral zones in a man over 60.
Bladder
PZ
CG
Rectum
Prostate
CG
PZ
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Figure 14. Normal looking seminal vesicles.
MR imaging of the prostate most commonly employs T2 and T1 weighted
imaging with most systems operating at 1.5 Tesla. This has produced
variable results for staging accuracy, in particular for detecting ECE and SVI.
Rouvière et al., in a meta-analysis of 10 studies all performed at 1.5 Tesla
[Table 6], reported staging accuracy rates ranging from 60-80%, with a mean
sensitivity and specificity of 53% and 83% respectively [95].
In another meta-analysis study, the authors summarized the receiver
operating characteristic curve from 23 reports which described the
performance of MR imaging, using a field strength of 1.5 Tesla or less, to
stage prostate cancer. They found a maximum pooled sensitivity and
specificity of 74% [96]. As a result, MRI has not been widely accepted by
urologists, especially for patients with low risk of extracapsular disease [97].
Bladder
Seminal Vesicles
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N Se (%) Spe (%) PPV (%) NPV (%) Accuracy (%)
Outwater et al 30 68 72 32 - 71
Harris et al 50 57/20a 61/100a 36/100a 79/65a 64/68a
Jager et al 34 36 89 36 88 79
Chefchaomi et al 47 52 100 100 72 79
Presti et al 56 91 49 51 90 -
Yu at al 77 82/47/59b 72/74/67b 70/59/59b 84/64/67b 77/62/64b
Bates at al 20 38 100 - - -
Yu et al 53 54/17c 95/94c 76/44c 88/79c 85/76c
Ikonen et al 44 22 99 - - 95
Corund et al 336 38 94 - - 77
N number of patients; Se sensitivity; Spe specificity; PPV positive predictive value; NPV
negative predictive value.
a Results obtained in the 25 first cases/25 last cases
b Results obtained by independent readers with an experience of 3 years/1 year/6 months
c Results obtained by independent readers with an experience of 5 years/2 years
Table 6. Detection of extracapsular tumour extension on T2 weighted
imaging at 1.5T (Rouvier et al)
3 Tesla (T) whole body MR scanning has come into clinical practice since
2002. The rationale for using 3T MR systems is that the higher static
magnetic field strength increases the signal intensity achieved without
altering the noise. In comparison with 1.5T the signal-to-noise ratio (SNR)
[98, 99] is increased by approximately a factor of two at 3T. The increased
SNR can be used for higher resolution imaging or reduction in scan time. By
employing parallel imaging techniques, the temporal resolution of the MR
measurements can also be significantly improved. Better spatial resolution
results in the use of a smaller voxel size and hence an improvement in the
pathoanatomic details compared to 1.5 T [100].
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Additionally the superior temporal resolution for any given region of interest
provides better delineation of changes in tissue signal intensity observed
during contrast administration. As a consequence of these improvements, the
use of MRI for prostate staging is being revisited at 3T with promising early
results. In 2006, Kim et al examined the detection and depiction of prostate
cancer using dynamic contrast-enhanced MR imaging (DCE-MRI) at 3T
[101]. The sensitivity, specificity, and accuracy for prostate cancer detection
were 55%, 88% and 70% for T2-weighted imaging and 73%, 77%, and 75%
for DCE-MRI, respectively. Futterer et al assessed the staging accuracy of
prostate MRI at 3T compared with histopathology. The author reported 94%
accuracy, 88% sensitivity, and 96% specificity for local cancer staging [102].
Researchers have used different techniques to identify malignant lesions and
stage the disease and have compared the results with either TRUS biopsies
or radical prostatectomy specimen pathological findings. Different methods
were used including endorectal coil imaging, diffusion weighted imaging,
spectroscopy and DCE-MRI at 3T to improve detection and staging accuracy
rates for cancer.
2.6. Basic MR Principles
2.6.1.MRI components:
An MR system consists of the following components:
1) A large magnet to generate a strong magnetic field. Magnetic field strength
is measured in units of gauss (G) or Tesla (T). One Tesla is equal to 10,000
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gauss (the earth's magnetic field is about 0.5 gauss). A 3T MR scanner (GE
Healthcare Ltd.) is used in our centre.
2) A radiofrequency (RF) coil is used to transmit a radio signal into the body
part being imaged to excite the protons.
3) A receiver coil is used to detect the returning radio signals. An example of
a receiver coil is a surface coil composed of a loop of wire, either circular or
rectangular, that is placed over the region of interest. Another example is an
endorectal coil which is placed in the rectum close to the posterior aspect of
the prostate. This provides better signal-to-noise ratio and hence better
image resolution.
The effective field of view (FOV) is proportional to the diameter of the surface
coil, while the signal-to-noise ratio (SNR) is inversely proportional to the coil
size. Therefore, a small surface coil provides the best SNR, but has a limited
FOV. This led to the development of phased-array coils, which contain a
number of small coils that are used simultaneously to receive the MR signal
and reconstruct a composite image. Phased-array coils provide a large FOV,
but with the SNR of a small surface coil. This provides a higher spatial
resolution and allows thinner slices to be acquired.
A further advance in coil usage includes the development of an integrated
endorectal-pelvic phased-array coil. This gives a combined image from both
coils for improved SNR and thus better visualization of anatomy [Figure15].
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Figure 15. Prostate MR Image using integrated endorectal-pelvic
phased-array coil. The endorectal coil is seen in the rectum and filled
with air to stabilize it. Axial image (a) and coronal image (b) showing
great anatomical details.
4) Shim coils to make the magnetic field as homogeneous as possible.
5) Gradient coils to produce deliberate variations in the main magnetic field
(B0). There are usually three sets of gradient coils, one for each direction,
namely x, y and z. The variation in the magnetic field is used to provide
spatial localisation of the signals.
6) A computer to reconstruct the radio signals into the final image.
2.6.2.Basic physics:
Protons have a positive electrical charge and are constantly moving like a
spinning top. This movement induces a local magnetic field. When a nucleus
is placed in the magnetic field of an MRI scanner, proton nuclei align with the
main magnetic field (B0) in two ways: parallel and anti-parallel. The parallel
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position is slightly favored, as the nucleus is at a lower (preferred) energy in
this position. This results in a net magnetisation pointing in the longitudinal
direction of the main magnetic field and this forms the basis of the MR signal.
Exposure of individual nuclei to radiofrequency (RF) energy (B1 field) causes
nuclei in the lower energy state to jump into the higher energy state, which
causes the net magnetisation to spiral away from the B0 field (anti-parallel).
This causes a decrease in the longitudinal magnetisation (potentially to zero)
and also establishes a transversal magnetisation due to the spinning
movements of the protons, [Figure 16] which is termed precession. After a
certain length of time, the net magnetisation vector rotates through 90
degrees and lies in the transverse or x-y plane. This rotating angle is called
the flip angle.
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Figure 16. : Longitudinal magnetic vector (a) at B0, a new transverse
magnetic vector is formed and decrease in longitudinal vector when
applying RF pulse (b), longitudinal vector may disappear depending on
RF pulse (c). Modified from original Source: MRI from A to Z: A
Definitive Guide for Medical Professionals by Gary Liney [103].
The proton spins return to equilibrium when the RF pulse is stopped.
Therefore, the transverse magnetisation disappears and the longitudinal
magnetisation grows back to its original size. Different “pulse sequences”
can be achieved by changing the strength, duration and nature of the RF
pulse given.
a b c
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2.6.3.T1, T2, TR and TE
T1 relaxation:
This is characterized by the return of the longitudinal magnetisation in the
direction of the main magnetic field to its ground state, so called the
longitudinal relaxation. It is associated with loss of energy to the surroundings
the so-called lattice, hence the name spin-lattice relaxation. The T1
relaxation time is the time for the longitudinal magnetization to recover to
69% of its original length. . Five times T1 indicates full recovery.
T2 relaxation:
This is characterized by the loss of the transverse magnetisation. This is not
associated with loss of energy to the surrounding lattice, therefore, it is called
spin-spin relaxation. The T2 relaxation time is the time for 69% loss of signal
due to dephasing. Five times T2 would be full loss of transverse
magnetisation.
Different tissues have varying T1 and T2 relaxation times. For example,
water has a long T1 and a long T2, whereas fat has shorter T1 and T2.
Time to repetition (TR):
This is the time taken to repeat the RF pulse [Figure 17]. Using a short TR
helps to differentiate between tissues by their differences in T1 relaxation
time, since tissue with a long T1 time will be hit by the next RF pulse before
the longitudinal vector grows back to its original size, leading to a short
transverse vector in the subsequent excitations. The resulting picture
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showing the differences in signal intensity of tissues due to the differences in
T1 relaxation time is called a T1-weighted image.
Time to echo (TE):
This is the time between the initial 90 degree RF pulse and the spin echo (the
signal received after the 180° pulse) [Figure 17]. Sending a 180° pulse at a
certain time (half of TE) makes the protons turn around and precess in the
opposite direction which enhances the signal returned from tissue. Using a
long TE time helps to differentiate between tissues by maximising the
differences in T2 relaxation times. Tissues with long T2 relaxation times,
such as fluid, give a higher signal on T2 weighted image.
Figure 17. Spin echo pulse sequence showing the time to repetition
(TR) between two radio frequency pulses giving two signals, and time
to echo (TE) between the initial 90 degree RF pulse and the signal
received after 180 degree RF pulse.
90°
180°
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A T2 weighted image has a long TR  and a long TE. A T1 weighted image
has a shorter TR and a short TE.
A proton density image has a long TR and a short TE. It is neither T1 nor T2
weighted, but is mainly affected by the difference in proton density present.
The more protons, the higher the signal obtained. Using the spin echo pulse
sequence, the timing can be adjusted to give T1-weighted, proton density, or
T2-weighted images.
In the prostate gland, the peripheral zones are formed mainly by glandular
tissue which contains a high concentration of fluid and therefore has a long
T2 and T1 resulting in high signal intensity on T2 weighted image (looks
bright). In prostate cancer, there is displacement of fluid within the acini by
tumour, which leads to a shorter T2 (looks dark on T2 weighted imaging)
[figure 18].
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Figure 18. T2 weighted image of prostate using the pelvic phased array
coil (a) and the endorectal coil (b). This shows a normal left peripheral
zone (bright) and a malignant lesion in the right peripheral zone (dark).
Brightness flare occurs in the peripheral zones of the gland due to the
proximity of the coil to the gland and signal decrease in the anterior
part of the gland.
a b
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Blood products present in the prostatic tissue secondary to haemorrhage
following biopsy have short T1 and T2, therefore look dark on T2 weighted
images and bright on T1 weighted images [Figure 19].
Figure 19. T2 weighted images using the pelvic phased array coil,
showing an area of low signal intensity in the left peripheral zone (a).
Same lesion is seen on endorectal imaging (b). T1 weighted image
showing the corresponding location with an area of haemorrhage seen
as a “bright” area in the left peripheral zone (c).
The scan time is mainly affected by TR, matrix size and number of
excitations (NEX). Increasing any one of these parameters increases the
minimum scan time.
The matrix is an array of numbers in rows and columns (frequency and
phase encoding steps). A matrix with m rows and n columns is called an
m x n matrix (m and n are called its dimensions). The MR matrix is used
to determine the scan resolution. Increase in matrix size produces better
a b c
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scan resolution, but increases the scan time. For relatively high
resolution prostate imaging we used a matrix of 384 x 256.
The number of excitations (NEX) refers to the repetition of the signal
measurements several times. By summating the signal generated, the SNR
is improved resulting in better image quality, but the imaging time increases.
Spatial resolution determines how "sharp" the image looks. Low resolution
will give either fuzzy edges, or a pixelated appearance to the image. Spatial
resolution is determined by matrix size and field of view (FOV). Increasing
the matrix size or decreasing the FOV increases spatial resolution, but at the
expense of either decreased signal-to-noise or increased scan time. To
obtain images of high resolution with high signal-to-noise requires longer
scan times.
Field of view (FOV) is the image area that contains the region of interest
to be examined. It is defined in units of mm². Dividing the FOV size by the
matrix size gives the voxel size; hence, increasing the FOV in either direction
increases the size of the voxels and decreases the resolution. The smaller
the FOV the higher is the resolution and the smaller the voxel size.
Choice of FOV size depends on the clinical question that needs to be
answered. In prostate imaging a large FOV covering the pelvis with a
reasonable image resolution is obtained to assess the pelvic lymph node
status and bony pelvis [Figure 20a], whereas a smaller FOV with much
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higher image resolution is obtained to image the prostate and assess
tumour location and capsular involvement [Figure 20b]
Figure 20. Low resolution pelvic image (a) is useful for detecting pelvic
lymph node disease and bony disease, whereas high resolution image
(b) is mainly to look at the prostate anatomy and pathology.
Choosing the best slice thickness is very important to answer the clinical
question. Thin slices covering only the studied organ give precise details to
a) Low resolution, high
FOV image
Image parameters:
FSE-XL;
TR=4000 ms; TE=97 ms;
BW 31.7;
thk=5mm, 1mm gap;
matrix=512x384, 2NEX;
FOV 24x24;
acq time=5:49
b) High resolution, small
FOV image
Image parameters:
FSE-XL;
TR=3000 ms; TE=97 ms;
BW 41.7;
thk=3mm, 0mm gap;
matrix=384x256,
4NEX;
FOV 20x20;
acq time=6:50.
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identify abnormalities for that organ. Thicker slices with wider field of view
are useful in overall assessment of the surrounding structures.
Signal-to-noise (SNR) ratio is measured by calculating the difference in
signal intensity between the area of interest and the background. Many of the
scan parameters affect signal-to-noise. The signal within an image can be
improved by increasing TR, FOV, slice thickness and NEX or by decreasing
TE and matrix size.
2.6.4. Contrast agents and dynamic contrast enhanced MRI
(DCE-MRI)
Dynamic contrast enhanced imaging techniques use fast MRI sequences to
repeatedly image a volume of interest during the intravenous administration
of contrast agents. MR contrast agents such as gadolinium di-ethylene-
triamine-penta-acetic acid (Gd-DTPA) were first introduced into clinical MR
practice by Heywang et al in 1986 [104]. This was the first paramagnetic
agent approved for clinical use, and was used initially for breast and brain
MR imaging.
Gadolinium is a low molecular weight paramagnetic agent which is toxic in its
free state; hence it is bound to DTPA to prevent toxicity. It has an effect on
signal intensity by shortening T1 and T2 relaxation time, based on the
assumption that there is a linear correlation between the tissue concentration
of Gd-DTPA and the longitudinal relaxation rate, R1 [105]. Therefore, it
causes an increase in the signal intensity of tissue on T1-weighed images
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(which is the predominant imaging technique used after contrast medium
injection). This is termed enhancement. Tissues that take up contrast look
bright on T1 weighted imaging [Figure 21].
a
b
Figure 21. T1 weighted images of the prostate. Pre (a) and post (b)
contrast administration. The area suspicious of malignancy on the left
PZ, takes up contrast and looks bright on T1 weighted image post-
contrast. Also note the enhancement of the vessels.
Following the intravenous injection of Gd-DTPA, it is rapidly distributed
throughout the blood plasma extravasates into the interstitial space (wash-in
phase) and then diffuses back into the vasculature (wash-out phase). Since
the GD-DTPA is not distributed equally throughout the body, but is taken up
by vascularised tissue, signals from different tissues will be affected
differently. This causes an enhancement of vascular malignant tumours and
these can be identified from the surrounding non-enhanced tissues [Figure
22].
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Figure 22. Showing the enhancement of malignant tissue in the prostate
gland, which is not otherwise seen on T2 weighted imaging. On the left
is a T2 weighted image showing a slightly darker right peripheral zone
compared to the left but not diagnostic of cancer. On the right is the
contrast enhanced image showing the increased uptake (demonstrated
by the red areas) in both peripheral zones. Histology confirmed cancer
in the areas highlighted in red.
The time course of the enhancement effects reflects the status of tissue
microcirculation and can be monitored by dynamic contrast-enhanced MRI
(DCE-MRI). DCE-MRI was introduced by Kaiser et al in 1989 [106]. It was
initially studied in breast MRI. The authors acquired images of the region-of-
interest pre contrast and subsequently every 60 seconds during and after
contrast injection giving a time course of images. They measured the signal
intensity changes that occurred in the early post contrast period.
By dynamically acquiring MR data, it allows generation of tissue contrast
concentration time curves which can be used in pharmacokinetic studies. In
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other words, it allows measurement of the signal intensity (SI) of regions of
interest (ROI) before arrival of contrast agent (base line); and observes the
increase in SI during the wash-in phase and the decrease of SI during the
wash-out phase. As well as construction of SI time curves [Figure 23] this
technique allows the measurement of various dynamics parameters of
contrast enhancement, such as maximum enhancement Index (MaxEI), time
to maximum enhancement (Tmax), initial and final
slopes.
Figure 23. Signal intensity – time curve for a typical malignant lesion:
The enhancement curve consists of an early upslope to reach peak
intensity and a wash-out phase. The figure shows the time point at
which contrast reaches the prostate (a) and the maximum enhancement
(b) achieved. Time to maximum enhancement (a-b), initial and final
slopes can be obtained as shown.
Maximum enhancement index (MaxEI) is defined as the peak SI achieved
during the dynamic examination. Time to maximum (Tmax) is defined as the
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time taken for the SI to reach its maximum (MaxEI). Enhancement index at
30s (EI at 30s) is defined as the percentage rise in signal at 30s, compared
to the initial pre-contrast signal. Initial slope is defined as the SI change in
the first 30s following contrast administration. This reflects the wash-in
phase. Final slope is defined as the SI change for the final 2 minutes of the
SI time curve. This reflects the wash-out phase. The area under curve (AUC)
is defined as the integral of the percentage enhancement over the first 4
minutes of contrast uptake.
These parameters were found to be strongly related to tumour blood flow,
the capillary permeability, and surface area. They have been used
successfully to differentiate between cancer and normal tissue in the breast,
bone, and brain. Kuhl et al [107] subdivided the signal intensity time curve
into three types depending on the curve shape: type I, a steady
enhancement; type II, signal intensity reaches a plateau after the initial rise;
or type III, washout of signal intensity occurs during the duration of the
examination. The authors found that the shape of the signal intensity time
curve is an important factor in differentiating between enhancing benign and
malignant lesions, as the type III time course is a strong indicator of
malignancy [Figure 24].
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Figure 24. Shapes of signal intensity curves as demonstrated by Kuhl et
al. Type I shows continuous enhancement throughout the dynamic
study, either as a straight line Ia or curved line Ib. Type II is a plateau
curve following an upstroke. Type III is a rapid washout time course.
Using this method, Kuhl reported a sensitivity of 91%, a specificity of 83%
and an accuracy of 86% in distinguishing benign from malignant breast
lesions [107].
Pharmacokinetic modelling is a mathematical process that uses all the signal
intensity data to give numeric values relating to the permeability and the
contrast exchange rate between the plasma and the extra-vascular extra-
cellular space (Ktrans), the blood volume (Vb) and extra-cellular extra-vascular
volume (Ve) of a region of interest.
Studies have demonstrated altered pharmacokinetic parameters in regions of
increased enhancement in the prostate when compared with normal
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peripheral zone at 1.5T [108, 109]. These parameters can be used to
differentiate benign from malignant lesions objectively and may provide
additional information useful in diagnosis, staging and localisation.
Schlemmer et al [110] demonstrated an association between the
pharmacokinetic parameters obtained from DCE-MRI and tumour
angiogenesis, in particular, microvascular density in prostate cancer.
Pharmacokinetic modelling also allows researchers to display Ktrans maps
[Figure 25] for better identification of tumour site and extent based on
abnormal vascular morphology.
Figure 25. PK map (right) showing an area of increase permeability
which correlates with low signal intensity on the corresponding T2
weighted image (left).
There has been a significant rise in the clinical use of DCE-MRI in prostate
cancer. Although T2 weighted imaging can show the areas of malignancy in
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the peripheral zones of the gland, other pathologies such as haemorrhage
and scarring can mimic the appearance of tumour on T2 weighted imaging,
leading to low sensitivity [111], while other tumours may be isointense with
normal tissue leading to a low specificity [103]. This led to the inclusion of
DCE MRI as part of the MR investigations for prostate cancer. It has become
a promising diagnostic tool in the management of prostate cancer through its
ability to spatially map the increased microvascular density and permeability
that is associated with malignant tumour growth. DCE has been shown to
significantly improve prostatic tissue characterisation and in turn the
diagnostic and staging accuracy. At 1.5T, DCE-MRI improves accuracy,
sensitivity and specificity for prostate cancer detection by 26%, 31% and
22% respectively relative to T2-weigted imaging as reported by Kim et al
[112]. The same group assessed the used of DCE MRI at 3.0T, with higher
temporal and spatial resolution, and again found it to be superior to T2-
weighted imaging since 15 out of 64 cancers were detected only by DCE
MRI.
The diagnostic accuracy of DCE-MRI in prostate cancer is further discussed
in Chapter 3.
2.6.5.Diffusion weighted imaging:
Diffusion weighted imaging (DWI) is an MRI technique that is dependent on
the random movement of water molecules (Brownian motion) in the studied
organ. This reflects the diffusion of water in the interstitial space, providing
information on the biophysical properties of the tissue such as extracellular
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fluid, cell density and tissue organisation. The diffusion properties of the
tissue examined can be quantified by calculating the diffusion coefficient of
water, known as the apparent diffusion coefficient (ADC). It is called
apparent because its value is influenced by the water diffusion as well as
other factors including perfusion and T2 relaxation time of tissue. It can be
calculated by acquiring a minimum of two images with different gradient
duration and amplitude (b value). The b value is a parameter that reflects the
degree of diffusion weighting. The ADC can be mapped on to an anatomical
image, using diffusion as the contrast. This allows visual assessment of the
location of the tumour as it appears as an area of decreased signal [Figure
26].
Figure 26.  Diffusion weighted image of prostate gland (a) showing an
area of low signal intensity in the right peripheral zone representing a
malignant lesion. Corresponding ADC map reflecting low ADC in right
peripheral zone using b-values of 0 and 500 s/mm2 (b).
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The acquired map depends on the spatially distributed diffusion coefficient of
the region of interest which is independent from T2 weighted value.
Diffusion-weighted imaging has the distinct advantage of being acquired very
rapidly, and creating an enhancement map without the use of contrast.
In 1950, Hahn et al discovered that the MR signal was influenced by
diffusion. In 1965 when Stejskal and Tanner [113] introduced the pulsed
gradient spin echo the development of diffusion weighted imaging (DWI)
began. It is the only technique that is able to assess molecular diffusion in
vivo and it has been shown to have diagnostic potential.
The first successful clinical application of DWI was in imaging the brain of
patients who had suffered from acute stroke. Areas which were injured during
a stroke showed up "darker" on an ADC map compared to healthy tissue
[114]. MR diffusion weighted imaging was then examined in breast cancers
and reduction in ADC values was noted in malignant breast lesions [115,
116].
The role of DWI in prostate cancer has been evaluated and the technique
found to be feasible. The extensive ductal structure of the normal prostate
compared with the highly restricted intracellular and interstitial spaces
encountered in prostate cancer, produces substantial differences in water
diffusivity and thus the potential for high image contrast.  The clinical role of
DWI in prostate cancer evaluation has been studied on 1.5 and 3.0T field
strength scanners. Reports have shown its efficacy, as a sole technique, in
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differentiating cancer lesions from normal peripheral zone (PZ) [117-120] with
sensitivity and specificity for tumour identification ranging from 84 to 94% and
72 to 91% respectively. Miao et al [121] showed that DWI has a better
performance in prostate cancer detection compared with T2 weighted
imaging alone (area under the ROC curves of 0.89 for DWI versus 0.82 for
T2w imaging). These findings were supported with results from other studies
[122, 123] which have also showed the superiority of combined DWI and T2
weighted imaging compared to T2 weighted imaging alone (AUC of 0.89-0.93
versus 0.81-0.87 respectively). Mazaheri et al [124] also showed the
improved differentiation between tumour and PZ using combined data from
DWI and spectroscopy compared to spectroscopy alone (AUC of 0.85 versus
0.74 respectively).
With advances in MR gradient coils, single shot echo planar imaging (EPI)
has emerged as the technique of choice for diffusion measurements in the
prostate providing better resolution ADC images [125]. A study by Issa et al
[126] using EPI DW imaging also showed statistical differences in ADC
values between normal PZ, BPH and cancerous prostatic regions.
In Chapter 4, I describe my experience in MR diffusion imaging on a 3.0T
system using whole mount radical prostatectomy specimen as a reference.
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Chapter Three
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3. THE CLINICAL ACCURACY OF MULTI-SEQUENCE
MRI AT 3 TESLA IN LOCALISING AND STAGING
PROSTATE CANCER
3.1. Objective
The aim of this study is to assess the accuracy of 3 Tesla MRI for cancer
staging and lesion localisation in patients with newly diagnosed prostate
cancer. High resolution T2 weighted images, endorectal imaging, and
dynamic contrast-enhanced MRI (DCE-MRI) were used and compared with
pathological findings from whole mounted radical prostatectomy (RP)
specimens.
3.2. Methods
3.2.1.Patients selection
Approval from the Local Ethics Committee was granted to analyze data from
patients who were scanned at the University of Hull, Centre for Magnetic
Resonance Investigations (CMRI).
All patients had histological confirmation of prostate cancer diagnosis based
on trans-rectal ultrasound guided biopsy (TRUS). This was performed by a
consultant radiologist or an experienced sonographer from Hull and East
Yorkshire NHS Hospitals.
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Patients were then reviewed in the outpatient urology clinic to discuss the
diagnosis of prostate cancer, explain further staging methods and the
treatment options. All patients who are considered for radical prostatectomy
were referred for MR prostate examination for radiological staging. Patients
who had a contraindication to MRI were excluded.
The MRI examination was performed approximately six weeks following the
TRUS prostate biopsy to allow the prostatic haemorrhage and inflammation
to resolve in order to reduce MR artifacts.
3.2.2.Patients preparation
On arrival at the CMRI, patients were interviewed to check suitability for
scanning and were asked to complete and sign a safety questionnaire,
having read and understood all the questions. They were also asked to
indicate if they were happy for their scans to be used for research purposes.
A data sheet was completed by the doctor overseeing the MR examination
detailing relevant history, investigations and the indication for performing
prostate MRI. The MR examination was then explained in detail to the
patient.
A 20 gauge Venflon® was placed in a vein on the dorsum of the hand or in
the ante-cubital fossa. Patients were positioned supine on the examination
table and entered the bore of the magnet feet first. Earplugs were provided to
protect against the scanner noise, as the scanner acoustic levels may
79
exceed 99 dB and can cause hearing impairment. Earplugs have a noise
reduction rating of at least 28 dB. A safety squeeze ball was given to patients
to trigger an alarm in case of emergency or feeling unwell.
For contrast injection, we used a disposable MRI kit (Spectris Solaris,
Medrad) consists of a 65 ml syringe for contrast media, a 115 ml syringe for
saline. A 2438 mm long low pressure connector tube was attached to both
syringes at one end and to the Venflon at the other. This was used to achieve
rapid delivery of the MR contrast agent followed by 15 ml of saline flush. 80
ml of saline for continuous slow flushing was used to keep the cannula
patent.
A 3.0T 8-channel pelvic phased-array coil (GE Healthcare) was used for
pelvic imaging. The coil consists of 2 pieces, a posterior section lying under
the patient, and an anterior section positioned over the region of interest. The
two sections of the coil are aligned in the z-direction and their relative
positions maintained using Velcro straps [Figure 27]. The coil is housed in a
soft, flexible foam material for patient comfort and safety. While the patient is
being advanced into the scanner bore, a laser light is aligned with the centre
of the coil for accurate positioning of the region of interest within the bore.
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Figure 27. A 3 Tesla 8 channel torso phased-array coil. The figure
shows the anterior and posterior elements connected with Velcro
straps. The plastic inner bridge can be positioned over the patient to
support the anterior elements if the weight of the device is
uncomfortable.
Two bags of Manganese Choride (2.5L each) were applied on patient’s pelvis
to reduce the dielectric effect. MRI scanning was performed after intravenous
injection of 20 mg of hyoscine-N-butylbromide (Buscopan, Boehringer
Ingelheim Ltd) to suppress bowel peristalsis. No bowel preparation was
required.
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3.2.3.MR examination
73 consecutive patients (mean age 62 years, range 51-71), with biopsy
proven prostate cancer, underwent imaging at 3.0T MR system (Signa HDx,
GE Healthcare, Milwaukee, USA) using multi-sequence MRI including T2
weighted, DCE-MRI, and an 8-channel phased array and an endorectal coil
for signal reception (as detailed below), before undergoing radical
prostatectomy (RP).
The following sequences were obtained:
 Three plane localizer
 Low resolution axial T2 weighted fast spin-echo (FSE) images to
assess pelvic lymph nodes and bones, covering the area from the
perineum up to the aortic bifurcation.
 High resolution axial and coronal T2 weighted FSE to assess the
prostate and surrounding structures (TR/TE: 3100/97.3 ms, slice
thickness: 3.0 mm, inter-slice gap 0.0 mm, matrix 384 x 256, field of
view 20 x 20 cm, number of slices 26, TA 6:50 mins). The axial T2w
images were obtained in a plane perpendicular to the long axis of the
gland.
 T1 weighted DCE-MRI was acquired axially using 3D Fast Spoiled
Gradient Recalled (FSPGR) sequence (28 flip angle, field of view 30
x 30cm, matrix 256 x 128, 24 locations per slab, TR/TE 5.1/2.1 ms,
parallel imaging factor of 2, temporal resolution 8.36 s per volume,
providing 35 slice locations in approximately 4:45 mins). This was
obtained immediately before, during and after bolus administration of
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0.1 mmol/kg body weight Gadolinium-DTPA based contrast agent
(Omniscan, Nycomed-Amersham, Norway) at a rate of 3 ml/s using a
power injector (Spectris Solaris, Medrad, Indianola, Pennsylvania)
followed by 15 ml saline flush.
 Endo-rectal imaging was then performed in 33 patients. For the first 14
cases a rigid ERC (Global Research Centre GRC, Münich, Germany)
was used in isolation to obtain the images. For the remaining 19 cases
(following a hardware upgrade) an integrated endorectal-pelvic
phased array inflatable coil was obtained and used [figure 28].
Figure 28. Endorectal coil with inflatable balloon to ensure retention
which can be integrated with pelvic phased array coil.
The insertion of endorectal coil was facilitated using lubrication.
Following insertion, the covering balloon was insufflated with 60 ml of
air and the coil was pulled back and secured in position. The
endorectal coil has the tendency to migrate cephalad during the
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inflation of the balloon, resulting in suboptimal visualization of prostate
apex. Therefore, gentle traction on the coil was applied as the balloon
was filled. The endorectal coil was then connected to the PPA coil.
The following sequence parameters were obtained (TR/TE:
variable/166.8 ms, slice thickness 2.5 mm, no inter-slice gap, matrix
256 x 224, field of view 14 x 14 cm, number of slices 22 obtained over
3:35 mins).
All MR images were analyzed using an Advantage Windows Workstation
(GE Medical System), operating at 4.2-03 software level and using the
Functool software package.
3.2.4.MR image evaluation
MR images were reviewed by two independent readers (LWT and BZ).
Reader 1 has more than 15 years experience in MRI and reader 2 has 2
years experience in prostate MRI. Each series was assessed independently
for tumour localisation and staging using a standard form developed for this
project [Figure 29]. A final report using the combined sequences was also
documented.
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Figure 29. The proforma used by each reader to evaluate each series
independently. The area of tumour was drawn on the prostate
illustration.
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Tumour localisation
T2 weighted images and DCE-MRI were used to localize tumour presence in
the prostate gland. Hypointense areas in the high signal intensity peripheral
zone on T2 weighted images were considered as suspicious of prostate
cancer. Also homogeneous, irregularly shaped hypointense areas within the
central gland, which were identifiable separately from co-existing BPH
features and cysts, were considered as suspicious for malignancy. At DCE-
MRI, areas demonstrating early, rapid and intense contrast uptake with
subsequent plateau or wash-out phase (as described previously) were
considered suspicious for the presence of malignancy.
The prostate was divided into 12 areas (left and right, apex, middle and base,
anterior and posterior). Each area was assessed for the presence or the
absence of suspected malignancy.
Tumour staging
Capsular involvement was evaluated on the basis of five specific features
described in the literature as highly indicative of extra capsular extension
(ECE) [127]. These features were as follows: asymmetry of the
neurovascular bundles, obliteration of the recto-prostatic angle, irregular
bulging of the prostatic contour, low signal intensity within the periprostatic fat
and overt extracapsular tumour.
Seminal vesicle involvement (SVI) was suspected when focal low signal
intensity was present in one or both seminal vesicles on high resolution T2w
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images and contrast uptake evident on DCE images. Pelvic lymph nodes
were also assessed to exclude lymphatic metastases. Final staging was
recorded according to the TNM classification [61]. The likelihood of ECE and
SVI was rated with a 5-point scale [Figure 29].
3.2.5.Histologic evaluation
Radical retropubic prostatectomy was performed by an experienced
urological surgeon. A nerve sparing procedure was performed in all patients
except those with suspected locally advanced disease (T3) on MR imaging or
digital rectal examination, or patients with intermediate and high risk factors
according to D’Amico risk stratification. Lymph node dissection was also
performed in selected patients as per guidelines.
Prostatectomy specimens were examined after routine preparation. The
prostate was weighed and measured in three dimensions; fixed in 10%
formaldehyde for 24 hours, painted in colour coded inks to identify left and
right side, whole mounted and then sectioned at 5 mm intervals in a plane
perpendicular to the long axis of the gland. The orientation of sectioning was
performed to match the MR slice orientation. The sections were then
embedded in large paraffin blocks. 3 µm thick slices were cut from the
superior surface of each section and stained with hematoxylin and eosin
(H&E) for subsequent microscopic examination.
All tumour foci were outlined on the whole mount H&E slides by an
experienced pathologist [Figure 30]. Apical and basal sections were cut and
87
examined separately for the presence of cancer. The seminal vesicles were
also examined for any spread of cancer [Figure 31].
Figure 30. H&E slide of whole mount prostate specimen with cancer
foci outlined in red.
Figure 31. Sections obtained from prostatic apex (first 3 on left), base
(middle 3) and seminal vesicles (last 2 on right). Evidence of cancer
was noted in the apical sections (black dotted areas).
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Extra prostatic extension (T3a) was considered to be present on
histopathologic assessment if cancer cells were found beyond the capsule, in
the adjacent adipose tissue or in the perineural spaces of the neurovascular
bundles [82]. Stage T3b was diagnosed if cancer involved the seminal
vesicles. A positive surgical margin was defined as cancer cells touching the
inked surface of the prostate [82]. Tumours were staged as Tx if there was
focally no extracapsular tissue demonstrable at the site of margin positivity
where the prostate was incised through the capsule due to surgical error.
Details of the extracapsular extension for tumours were recorded. These
included the location and the degree of ECE [Figure 32].
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Figure 32. The proforma that was used to document pathology details
including localisation, staging and surgical margins.
90
3.2.6.Statistical analysis
Statistical analysis was performed using SPSS for windows (version 13.0).
Sensitivity, specificity, positive predictive value, negative predictive value and
accuracy for localizing prostate cancer were calculated using cross-tabulation
with the prostatectomy histopathologic results as the reference standard.
Kappa statistics were used to evaluate the inter-observer agreement
between the two readers. The following terms were used to describe the
strength of agreement: ĸ = 0 - 0.20, poor agreement; ĸ= 0.21 – 0.40, fair
agreement; ĸ= 0.41 – 0.60, moderate agreement; ĸ= 0.61 – 0.80, substantial
agreement; and ĸ= 0.81 – 1.00, near perfect agreement [128]. The probability
of extracapsular and seminal vesicle invasion was graded on a scale of 1-5,
which allowed for receiver operating characteristic (ROC) analysis and
obtaining descriptive statistics from 2 cutoff points.
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3.3. Results
3.3.1.Patients demographic data
All recruited patients were eligible for the study (73 patients). 31 patients
presented with lower urinary tract symptoms, whereas 4 patients presented
with urinary tract infection, one patient with acute urinary retention, one
patient with haematuria, and 36 patients were asymptomatic (cancer was
identified through the well-man clinic or screening).
Digital rectal examination identified 60 patients with clinical stage of T1c and
13 patients with T2 disease. Mean PSA was 7.6ng/ml (range 1-16). Gleason
score varied from 6 to 9 [Table 7].
Gleason score Number of patients (percentage)
3+3=6 20 (27.4%)
3+4=7 42 (57.5%)
4+3=7 4 (5.4%)
4+4=8 2 (2.7%)
4+5=9 5 (6.8%)
Table 7. Pre-operative TRUS prostate biopsy results. The majority of
cases that were suitable for RP were Gleason Grade 6 or 7.
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3.3.2.Localisation data
The 12 prostatic areas were combined into apex, base, mid anterior
(representing the central gland), and mid posterior (representing the
peripheral zone) to facilitate statistical calculations.
Histopathologic analysis
Pathological examination of RP specimens detected cancer foci in 177 areas
out of a total of 292 areas (73 patients multiply by 4 areas). The number of
cases with cancer involvement in individual areas is detailed in Table 8.
Number Percentage (the number of positive cases / total
number of patients x 100)
Apex 35 47.9%
Base 22 30.1%
Central gland 49 67.1%
Peripheral
zone
71 97.3%
Table 8. Mapping tumour presence on pathology slides showed that the
peripheral zone is most commonly affected by cancer compared to
central gland, base and apex.
66 patients (90.4%) had 2 or more tumour foci in the prostate gland. While
the majority affected the peripheral zones, only two cases had a central gland
tumour only. In 47 cases (64.4%) tumour was present in both peripheral
zones and central gland. In 12 cases (16.4%) all prostate areas had tumour
involvement.
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MRI data
The number of cases with suspicion of malignancy according to region is
detailed in Table 9 for T2 weighted imaging and in Table 10 for DCE-MRI for
both readers 1 and 2.
Number* Percentage (%)*
Apex 37/29 50.7/39.7
Base 39/21 53.4/28.8
Central gland 28/23 38.4/31.5
Peripheral zones 69/66 94.5/90.4
(* Results from reader 1 / results from reader 2)
Table 9. The number of cases, for each anatomical region, with T2
weighted features suspicious of cancer presence.
It is clear from Table 9 that, by using T2 weighted imaging, reader 1 assigned
173 areas as suspicious for cancer compared to 139 areas assigned by
reader 2. The main areas of discrepancy were the prostatic base and apex.
By using DCE-MRI, reader 1 assigned 164 areas as suspicious for cancer
compared to 144 areas assigned by reader 2. The discrepancy in the number
of suspicious foci identified in the prostatic base and apex areas is much less
compared to T2 assessment alone [Table 10].
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Number* Percentage (%)*
Apex 33/24 45.2/32.9
Base 31/21 42.5/28.8
Central gland 36/30 49.3/41.1
Peripheral zones 70/69 95.5/94.5
(* Results from reader 1 / results from reader 2)
Table 10. Represents the number of cases for each anatomical region
that showed high signal intensity following administration of contrast
for readers 1 and 2.
Interobserver agreement:
For T2 weighted imaging, there was an overall moderate agreement between
the two readers (K = 0.58). By selecting each region individually [Tables 11-
14] there was a moderate agreement in reporting an area as suspicious of
malignancy at the apex (K = 0.56), peripheral zones (K = 0.42), and central
gland (K = 0.55). However, looking at the base of the gland, there were 21
cases reported as suspicious for malignancy by reader 1 but not identified by
reader 2 with only a fair interobserver agreement (K = 0.36).
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Apex (T2 weighted)
Reader 2
Totalnormal
Suspicious
of cancer
Reader 1 normal 32 4 36
Suspicious
of cancer 12 25 37
Total 44 29 73
Table 11. The number of normal and suspicious cases at the apex for
both readers identified on T2 weighted imaging.
Base (T2 weighted)
Reader 2
Totalnormal
Suspicious
of cancer
Reader 1 normal 31 3 34
Suspicious
of cancer 21 18 39
Total 52 21 73
Table 12. The number of normal and suspicious cases at the base for
both readers identified on T2 weighted imaging.
Central gland (left &
right sides) T2w image
Reader 2
Totalnormal
Suspicious
of cancer
Reader 1 normal 99 6 105
Suspicious
of cancer 18 23 41
Total 117 29 146
Table 13. The number of normal and suspicious cases at the anterior
middle region (central gland) for both readers identified on T2 weighted
imaging.
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peripheral zones (left &
right sides) T2w image
Reader 2
Totalnormal
Suspicious
of cancer
Reader 1 normal 22 5 27
Suspicious
of cancer 24 95 119
Total 46 100 146
Table 14. The number of normal and suspicious cases at the posterior
middle region (peripheral zone) for both readers identified on T2
weighted imaging.
It is noted from all the above tables that both readers agreed in identifying the
majority of normal looking areas. However, for all anatomical regions of the
prostate, reader 1 identified more regions suspicious of cancer. These were
considered by reader 2 to be normal.
For DCE-MRI, there was an overall substantial agreement between the two
readers (K = 0.68). The best agreement was reached in the peripheral zone
region (middle posterior) with K = 0.65 and central gland (K = 0.68).
However, moderate agreement was noted in the apex (K = 0.57), base (K=
0.59).
Tables 15-18 illustrate the results for all anatomical regions for both readers.
Apex (DCE) Reader 2
Totalnormal Sus of ca
Reader 1 normal 37 3 40
Sus of ca 12 21 33
Total 49 24 73
Table 15. The number of normal and suspicious cases at the apex for
both readers identified on DCE-MRI.
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Base (DCE) Reader 2
Totalnormal Sus of ca
Reader 1 normal 40 2 42
Sus of ca 12 19 31
Total 52 21 73
Table 16. The number of normal and suspicious cases at the base for
both readers identified on DCE-MRI.
Central gland (left &
right sides) DCE image
Reader 2
Totalnormal Sus of ca
Reader 1 normal 89 4 93
Sus of ca 16 37 53
Total 105 41 146
Table 17. The number of normal and suspicious cases at the central
gland for both readers identified on DCE-MRI.
Peripheral zones (left &
right sides) DCE image
Reader 2
Totalnormal Sus of ca
Reader 1 normal 23 8 31
Sus of ca 9 106 115
Total 32 114 146
Table 18. The number of normal and suspicious cases at the peripheral
zones for both readers identified on DCE-MRI.
The main pitfall in the DCE-MRI agreement between the two readers was the
number of cases reported by reader 1 as suspicious for malignancy but
overlooked by reader 2. Those were 12/73 (16.4%) cases for apical region,
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12/73 (16.4%) for basal region, 16/146 (10.9%) for central gland, and 9/146
(6.1%) for peripheral zones.
Localisation accuracy (MRI versus pathology)
The MRI data was correlated with pathology data on a region by region
basis. Figure 33 is an example of the correlation between the MR using T2
weighted imaging and DCE and histopathology.
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Figure 33. T2 weighted image (left) demonstrating low signal intensity
in the left peripheral zone (black arrow). This correlates with high
contrast uptake on DCE image (middle). The correlation with H&E
stained histopathology slide (right) is also noted. There is an additional
small area of uptake in the right peripheral zone seen on DCE image
(white arrow) which correlated with scattered islands of malignant cells
seen histologically.
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The sensitivity, specificity, positive predictive value, negative predictive value
and accuracy of tumour localisation were determined after combining the
regions into apex, base, central gland, and peripheral zones. The results are
shown in Table 19 for T2 weighted imaging and in Table 20 for DCE-MRI
independently.
T2 weighted
FSE imaging
Sen (%) Spec (%) PPV (%) NPV (%) Acc (%)
Apex 74/48 71/68 70/58 75/59 72/58
Base 95/50 65/80 54/52 97/78 74/71
Central gland 53/38 91/83 92/82 48/40 65/53
Peripheral zone 91/73 57/53 90/87 59/32 84/69
Table 19. Sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of tumour localisation on T2 weighted
imaging. Results from reader 1 / reader 2 are provided for each
parameter.
Tumour localisation using T2 weighted imaging demonstrated over-
estimation of cancer presence in the peripheral zones signified by the high
sensitivity and low specificity. This may be as a result of low signal intensity
changes secondary to haemorrhage following prostate biopsy, leading to
high false positive rate. On the other hand, studying the central gland, there
is under-estimation of cancer with low sensitivity. This is most likely due to
the difficulty in identifying cancer separate from benign disease leading to a
high false negative rate.
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Similar results for sensitivity were noted using DCE-MRI [Table 20] with high
sensitivity for tumour presence for peripheral zones and lower sensitivity for
central gland. However, the specificity for peripheral zone is much improved
using DCE-MRI.
DCE-MRI Sen (%) Spec (%) PPV (%) NPV (%) Acc (%)
Apex 74/57 81/89 78/83 77/69 78/73
Base 90/72 78/90 64/76 95/88 82/84
Central gland 69/59 91/95 94/96 59/53 76/71
Peripheral zone 90/88 71/64 93/91 64/56 87/83
Table 20. Sensitivity, specificity, positive predictive value, negative
predictive value and accuracy for tumour localisation by DCE-MRI.
Results from reader 1 / reader 2 provided for each parameter.
On further analysis, the overall sensitivity and specificity for the whole
prostate gland (including all zones) based on T2 weighted imaging is 75%
and 76% respectively for reader 1 and 55% and 78% for reader 2. Whereas,
when DCE-MRI was applied, there was a noticeable improvement in the
above parameters especially for reader 2 who achieved a sensitivity of 70%
and specificity of 88% with an accuracy rate of 78% [Table 21].
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Whole
gland
Sen (%) Spec PPV NPV Accuracy
T2W 75/55 76/78 81/78 69/56 75/65
DCE-MRI 79/70 83/88 87/89 74/68 80/78
Table 21.  Sensitivity, specificity, positive predictive value, negative
predictive value and accuracy for tumour localisation in the whole
gland. Results from reader 1 / reader 2 detailed. An improvement in all
parameters was noted for DCE-MRI compared to T2 weighted imaging.
By utilizing DCE-MRI data, the less experienced reader achieved comparable
results to those obtained from the T2 weighted imaging reported by the
experienced reader (area under ROC curve of 79 versus 76 respectively)
[Figure 34]. This indicates the importance of using DCE sequence if the MRI
is reported by a general radiologist or a trainee as well as on a general basis.
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Figure 34. The ROC curve for tumour localisation using T2 weighted
imaging and DCE-MRI for reader 1 and 2. AUC for T2 w imaging is 76
and 67 for reader 1 and 2 respectively. AUC for DCE-MRI is 81 and 79
for reader 1 and 2 respectively.
3.3.3.Staging data
Histological staging data:
The majority of cases (56 cases, 76.7%) were staged as organ confined
disease (pt2). 15 cases (20.5%) had local invasion of cancer and were
staged as pt3 (11 as pt3a and 4 as pt3b). Two cases were not staged (Tx)
due to intra-prostatic positive margins at the site of cancer, therefore,
accurate staging could not be done. These two cases were excluded from
the staging analysis [Figure 35].
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Figure 35. Demonstrate the number and percentage of cases according
to pathological stage.
MRI detection of ECE:
Areas suspicious for ECE on MRI were compared with H&E slides as
discussed above [Figure 36].
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Figure 36. T2 weighted image (left) demonstrates a tumour involving the
left peripheral zone with an area suggestive of extracapsular extension
(white arrow). This corresponds with tumour extracapsular extension
on H&E histology slide (x10 and x20 magnification).
For readers 1 and 2, ROC curves for the detection of local extracapsular
extension on T2 weighted imaging using PPA coil alone [Figure 37], showed
that an AUC of 0.87 for reader 1 (95% confidence interval: 0.76 to 0.98) and
an AUC of 0.83 for reader 2 (95% confidence interval: 0.69 to 0.96). The
weighted k statistic was 0.43 which indicated moderate agreement between
readers.
106
Figure 37. ROC curves for T2 weighted detection of ECE using PPA coil
for readers 1 and 2.
Using endorectal coil imaging, the ROC analysis [Figure 38] showed a better
detection of ECE for reader 1 with an AUC of 0.93 (95% confidence interval:
0.84 to 1.0) and for reader 2 with AUC of 0.87 (95% confidence interval: 0.73
to 1.0). The weighted k statistic was 0.43 which indicated moderate
agreement between readers.
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Figure 38. ROC curves for T2 weighted detection of ECE using an
endorectal coil for readers 1 and 2.
The five point scoring system was dichotomized in order to assess the
sensitivity and specificity of T2 weighted imaging using PPA and endorectal
coil in demonstrating extracapsular extension. Two cutoff points were
explored. Cutoff point 1 assumed that values of 1 and 2 indicate the absence
of ECE and that values of 3-5 indicate the presence of ECE. Cutoff point 2
assumed that values of 1, 2 and 3 indicate the absence of ECE and that
values of 4 and 5 indicate the presence of ECE. Tables below demonstrate
the staging descriptive analysis for both readers at two cutoff points using a
PPA coil [Table 22] and an endorectal coil [Table 23].
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Sen (%) Spe (%) PPV (%) NPV (%) Accuracy (%)
Cutoff
1
67 (43 – 90) /
67 (43 -90)
93 (87 –99) /
87 (82 – 97)
71 (48 – 95) /
63 (39 – 86)
92 (84 – 98) /
91 (84 – 98)
88 (80 – 95) /
85 (77 – 93)
Cutoff
2
40 (15 – 64) /
31 (8 – 53)
92 (95–100) /
98 (95 – 100)
86 (60–100) /
83 (54 – 100)
86 (78 – 94) /
84 (75 – 93)
86 (78 – 94) /
84 (76 – 92)
Table 22. Staging descriptive analysis for detection of ECE from T2
weighted imaging for reader 1 / reader 2, using a pelvic phased array
coil. Sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy for two cutoff points. 95% confidence
intervals shown in parenthesis.
From the table above, it is clear that both readers have high specificity for
detecting extracapsular cancer extension with reasonable sensitivity of 67%.
As expected, reader 1 has a better staging accuracy than reader 2 due to
being more experienced in evaluating prostate MR imaging.
Sen (%) Spe (%) PPV (%) NPV (%) Accuracy (%)
Cutoff
1
67 (22 – 95) /
67 (22 – 95)
96 (80–100) /
92 (74 – 99)
80 (28 – 99) /
67 (22 – 95)
92 (72 – 99) /
92 (72 – 99)
90 (74 – 98) /
87 (70 – 96)
Cutoff
2
33 (4 – 77) /
50 (12 – 88)
100(86–100)/
96 (78 – 100)
100(16-100) /
75 (19 – 99)
86 (68 – 96) /
89 (71 – 98)
87 (70 – 96) /
87 (70 – 96)
Table 23. Staging descriptive analysis for detection of ECE from T2
weighted imaging for reader 1 over reader 2 using an endorectal coil.
Sensitivity, specificity, positive predictive value, negative predictive
value, and accuracy shown for two cutoff points. 95% confidence
intervals in parenthesis.
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Although no change in sensitivity between PPA and ERC data was noted,
there was an improvement in specificity and positive predictive value for both
readers. The results of reader 2 using endorectal coil are similar to those
achieved by reader 1 using pelvic-phased array coil. This might indicate the
necessity of using an ERC for trainees during the learning curve.
With regard to seminal vesicle involvement, a total of four cases of SVI were
observed on histopathology examination, but in only two of these cases did
combined T2 weighted and DCE MR imaging show changes suspicious of
cancer involvement [Figure 39].
Figure 39. An example of seminal vesicle involvement. Low intensity
areas seen in both seminal vesicles (left) with high contrast uptake on
DCE-MRI (middle). These findings correlated with tumour involvement
pathologically.
In addition, a further two cases which were positive on MRI were negative for
cancer on histological examination. One of these cases, the tumour abuts the
seminal vesicle but does not invade the muscular layer. This low sensitivity
and PPV is biased by the small number of cases with suspected SVI on MRI
who subsequently underwent RP. Due to the low number of SVI, a full
statistical analysis was not done.
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3.4. Discussion
Tumour staging:
At the present, the major role of MR imaging in prostate cancer is the
evaluation of local staging, especially the detection of extracapsular
extension.
In this study, the use of pelvic-phased array and endorectal coil in detecting
extracapsular extension displayed 67% sensitivity, 96% specificity, 80% PPV,
92% NPV, and 90% accuracy for the experienced reader. These staging
results are similar to the previously documented results in large centres using
3 Tesla MRI [102, 129]. This showed superior results for 3.0T compared to
1.5T MRI. Although we did not perform a comparative field strength study on
the same group of patients, the accuracy of staging at 3.0T was higher than
the historical reported data for 1.5T (60-80%) [96, 130].
Most radiologists report MR images leaning toward high specificity, but
maintaining reasonable sensitivity, to prevent overstaging which may lead to
a potentially curative surgical treatment being withheld on the basis of false
positive MR imaging result. In our centre, we also showed a reasonably good
sensitivity of 67% for cancer staging for the use of PPA and ER coils. In 15
cases with confirmed ECE on pathology, 10 cases were detected on MRI.
This was constant for both readers. For the remaining 5 cases, pathological
analysis of the specimen showed minimal microscopic invasion of cancer into
the prostate capsule only. Detection of microscopic invasion on imaging
remains impossible. In clinical practice, missing minimal microscopic
capsular invasion on MRI may not alter the patient’s management as there is
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growing evidence that radical prostatectomy as a primary treatment for early
T3 disease can achieve good cancer control and survival [131]. However,
detection of ECE on MR imaging, as demonstrated by a PPV of 80% using
an ERC, may affect the surgical technique, as a nerve sparing procedure
would not be performed on the suspicious side with the intention of achieving
better cancer control.
In a limited population of 27 patients considered for radical prostatectomy,
Augustin et al [129] compared the accuracy of 3T MRI with the Partin tables
for predicting pathologic stage. In the detection of extracapsular extension,
MRI had an accuracy of 85.2%, a sensitivity of 66.7%, and a specificity of
100%. Correlation with extracapsular extension was considerably higher for
MRI findings (Spearman r = 0.780) than for the Partin tables (Spearman r =
0.363). Overall, 3T MRI was significantly more accurate than the Partin
tables in predicting the final pathologic stage, and therefore should have
more impact on treatment decisions, especially with regard to nerve-sparing
procedure.
Staging according to D’Amico risk classifications:
There has been further debate amongst urologists and radiologists about
whether preoperative MRI should be employed only for intermediate and high
risk groups according to D’Amico risk stratification. Kim et al [132] analysed
the role of a combined DWI and DCE-MRI protocol (at 1.5T) in predicting the
local stage, and found high values of sensitivity 92.3%, specificity 93.1%,
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PPV 85.7%, and NPV 96.7%, when only cases with clinically high-risk
disease features were analysed.
Roethke et al [133], performed a subgroup analysis in 385 patients,
comparing the MRI staging data in low risk and intermediate/high risk groups.
The authors found no significant difference in specificity between groups, but
poor (and much lower) sensitivity of only 20% was reported in the low risk
group.
In a subgroup analysis of our data, we found high accuracy rates for both low
risk and intermediate/high risk groups [Table 24]. However, low sensitivity
was also noted for detection of extracapsular extension in the low risk group
(33%), similar to previous documented studies. These results could be
affected by the small number of patients with histologically confirmed
extracapsular extension in low risk group (one case in our cohort).
Low risk (PSA < 10
and Gleason = 6
Intermediate/high risk
(PSA ≥ 10 and
Gleason ≥ 7)
Patients (n) 20 53
Sensitivity (%) 33 81
Specificity (%) 100 88
PPV (%) 100 64
NPV (%) 89 95
Accuracy (%) 90 87
Table 24. Sensitivity, specificity, positive and negative predictive values
for prediction of ECE according to the D’Amico risk classification.
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Despite the documented low sensitivity in detecting ECE in low risk group,
MRI still carries great value for evaluation and counseling for two main
reasons:
1) About 25-30% of cases with a diagnosis of Gleason 6 PCa on
biopsy will be upgraded to Gleason 7 or above on
histopathology examination of the radical prostatectomy
specimen. These patients are therefore at a higher risk of
extracapsular extension and/or positive resection margins.
2) If MRI shows no evidence of tumour in patients with low-risk
PCa, it could represent an additional criterion to choose active
surveillance. In contrast, patients with visible tumour on MRI,
particularly in the case of large volume disease, may be
candidates for repeat biopsies to confirm tumour
aggressiveness, and thus suggest a radical treatment.
Tumour localisation:
The second important role of prostate MRI is the localisation of tumour within
the prostate gland. This has potential clinical benefits, including improved
accuracy of MR-guided biopsy, improved focusing of irradiation for intensity-
modulated therapeutic radiotherapy, and improved guidance of other modern
focal ablation techniques such as cryotherapy and high intensity focused
ultrasound. We used a whole mounted prostatectomy specimen as the ‘gold
standard’ reference test for clinical validation of MR imaging in localizing
tumour foci. However, there are emerging biopsy techniques such as
transperineal template biopsies which can obtain histology samples from the
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whole gland including the transitional zones at intervals of 5mm diameters.
These techniques are now acceptable as a standard reference test for
imaging evaluation without subject patients to major surgery.
In this study, the detection of prostate cancer within the prostate by T2
weighted alone is limited, with overall sensitivity, specificity, and accuracy of
75%, 76%, and 75% respectively for reader 1, and 55%, 78%, and 65%
respectively for reader 2. The lower sensitivity and higher specificity results
for reader 2, suggest over-estimation of cancer presence on T2 weighted
imaging. This limitation means that prostate cancer cannot be reliably
distinguished from other T2 hypointense lesions such as prostatitis,
haemorrhage and atrophy, all of which present with low signal intensity
changes.
DCE-MRI provides higher prostate cancer localisation accuracy than that
achievable by T2 weighted imaging alone, especially for the less experienced
reader, with accuracy rates of 80% versus 75% for reader 1, and 78% versus
65% for reader 2 respectively. Moreover, by using DCE imaging, reader 1
detected 15 pathologically confirmed tumour areas (1 apex, 9 central gland,
and 5 peripheral zone) that were not detected by T2 weighted imaging.
Similarly, reader 2 detected 34 tumour areas (7 apex, 6 base, and 21
peripheral zone) based on DCE imaging that were missed on T2 weighted
imaging.
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The best localisation results using DCE imaging were achieved in assessing
the peripheral zones with marked improvement in specificity from 57% to
71% for reader 1, and from 53% to 64% for reader 2. This high specificity
was achieved whilst maintaining a sensitivity of 90% and 88% for readers 1
and 2 respectively.
The prostate apex is the main problematic area to assess with MR imaging.
This is mainly because of the lack of a well-defined capsule to separate it
from the periprostatic tissues, and the presence of the neurovascular
bundles. This gives a relatively poor accuracy rate for both T2 weighted and
DCE MR imaging.
Our research outcome is comparable with results from previous published
studies. Delongchamps et al, in a study involved 57 patients, reported a
sensitivity of 79% and specificity of 92% using combined data for T2 and
DCE in the peripheral zones only. With regard to the transitional zone (TZ)
tumours, the author reported a sensitivity of 47% and a specificity of 77% for
tumour detection using DCE-MRI. In our study, the experienced reader
maintained a good sensitivity of 71% with a high specificity of 90%.
Reader’s experience:
Reader experience is one of the most important factors in accurate staging of
prostate cancer. A study at the Memorial Sloan-Kettering Cancer Centre
compared the detection of PCa extracapsular extension by genitourinary and
general body radiologists [68]. The authors demonstrated a significant
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increase in the detection accuracy of extracapsular extension when
endorectal MR images were interpreted by genitourinary radiologists
compared to general body radiologists with AUC values of 0.83 versus 0.64
respectively.
Another recent study compared the accuracy of MRI staging according to the
level of experience [134]. The paper showed that the experienced reader
reached a staging efficiency of 86.96%, whereas the less experienced reader
only reached a staging efficiency of 56.52%. The authors indicated that the
performance of a less experienced reader does not meet the expectations of
the technique, and they emphasized that MR imaging with a combined
phased-array and endorectal coil can achieve a good correlation with
histopathology in terms of local prostate cancer staging, but only if performed
by an experienced radiologist.
In this study the less experienced reader improved his localisation accuracy
by using dynamic contrast-enhanced MR imaging (accuracy of 65 versus 78
for T2W and DCE MRI respectively). The parametric maps generated on the
MR workstation helped draw the attention of the less experienced reader to
areas of prostate cancer. With regard to staging, the use of endorectal coil
mainly improved the staging specificity for the less experienced reader from
87% to 92%.
Therefore we believe that there is a considerable learning curve in the
interpretation of prostate MR images. A radiology trainee should be using the
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best available MR technology in terms of DCE-MRI and endorectal coil
imaging to achieve a maximum accuracy in staging and localising prostate
cancer.
One of the limitations in my study was the potential for verification bias. In our
department, MR imaging is performed in all patients who are considered for
RP. Therefore the result of MRI, especially the findings of overt ECE or SVI,
may have contributed to the decision to cancel RP. This bias could have
inflated the accuracy, sensitivity and specificity rates due to better selection
of organ confined disease at surgery. Correction for this verification bias
remains impossible.
Another point to note is that the histology sections were cut at 5mm intervals.
This means that tumours less than 5 mm diameter may get missed on
histological evaluation.  Therefore, there were not included in the MR
evaluation as these tumours were considered to be clinically insignificant.
This was agreed by the European consensus meeting in December 2009, as
the panel recommended excluding clinically insignificant cancer as defined of
a lesion smaller than 0.5 cm3 in assessing the detection rate for each MRI
sequence [135].
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3.5. Conclusion:
In conclusion, using 3 Tesla MRI, an experienced reader was able to localize
prostate cancer foci with good sensitivity and specificity overall, especially for
peripheral zones where most cancers occur. Using DCE-MRI further
enhances the sensitivity and specificity especially for non experienced
clinicians.
Endorectal 3.0T MR imaging achieves a high spatial resolution, revealing
excellent anatomical details to allow adequate staging and to facilitate clinical
decision making. Moreover, the experience of the reporting clinician is hugely
important to maintain a high accuracy rate with balance between sensitivity
and specificity.
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Chapter Four
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4. CORRELATION OF APPARENT DIFFUSION
COEFFICIENT WITH CELL DENSITY IN PROSTATE
CANCER
4.1. Objective
Notwithstanding the increasing use of DWI in prostate cancer imaging at both
1.5 and 3.0 Tesla, there has been no work examining the relationship
between ADC and histopathological variables such as cell density (CD).
Studies on breast, brain and metastatic prostate cancers suggest that a rise
in ADC values, caused by the loss of cellular density during effective
treatment, may provide an early quantitative assessment of positive tumour
response [115, 136, 137].
CD may be indicative of tumour aggressiveness, as several clinical studies
have indicated increased metastatic activity from highly cellular tumours [138,
139]. The increased cellularity of malignant lesions restricts water motion due
to a reduction in the extracellular space, thereby, resulting in lower ADC
values. Initial results have demonstrated a significant negative correlation
between the ADC values of tumour regions and cell density in breast
tumours, human gliomas, metastatic brain tumours and human melanoma
xenograft [116, 140-142]. Guo et al [116], showed that tumour cellularity has
121
a significant influence on the ADC values obtained in both benign and
malignant breast lesions, malignant regions with high cell density having a
lower ADC value than benign regions with a low cell density (r=-0.542).
To my knowledge, this is the first study assessing the diagnostic potential of
ADC parameters in prostate cancer via correlation with cell density
determined by hematoxylin and eosin stained whole mount radical
prostatectomy specimens.
4.2. Methods
Approval from the Local Ethics Committee was granted and written consent
obtained from all patients for their MR images to be used for research
purposes. Thirty two patients with biopsy proven prostate cancer were
recruited from December 2005 to December 2007. They were referred from
the Urology Department for MR staging prior to radical prostatectomy. The
mean age was 62 years, mean PSA was 7.6 ng/ml (range 2.5 - 16 ng/ml).
Gleason scores were as follow: 5 were Gleason 6 (3+3) ; 23 were Gleason 7
(20 cases Gleason 3+4 and 3 cases Gleason 4+3); 1 was Gleason 8 (4+4) ;
and 3 were Gleason 9 (2 cases Gleason 4+5 and one case Gleason 5+4).
The median interval between trans-rectal ultrasound-guided prostate biopsy
and MR examination was six weeks to allow the inflammation and
haemorrhage following biopsy to resolve; this was adequate to obtain good
quality diffusion images. None of the patients received any treatment prior to
MRI.
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MRI was performed on a 3.0 Tesla scanner (Signa HDx, GE Healthcare,
Milwaukee, USA) using an eight-channel pelvic phased array receiver coil.
Preparation of patients was as described in chapter 3. After conventional T2
weighted imaging, DW images were obtained axially using a single shot dual
spin-echo echo-planar imaging (EPI) sequence with b-values of 0 and 500
s/mm2. Other acquisition parameters included: TE = 65.7 ms (fractional
echo); TR = 4000 ms; matrix size = 224 x 224; field of view = 26 x 26 cm;
slice thickness = 5 mm; slice gap = 1 mm; average = 16; receiver bandwidth
= 250 kHz; total acquisition time = 2:08 minutes.
Patients then proceeded to radical retropubic prostatectomy as the sole
radical treatment. Prostatectomy specimens were prepared and examined as
described in chapter 3. Experienced pathologists outlined regions of tumour
on the H&E slides. Five randomly positioned areas from within the most
representative sections of the outlined tumour and separately from normal
peripheral zone were examined using x200 magnification, digitally
photographed and then analysed using ‘in-house’ developed MATLAB
software. This software utilises adaptive histogram thresholding to segment
the darker stained cell nucleus [Figure 40].
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Figure 40. Images of H&E stained prostatic carcinoma at x200
magnification, before (a) and after processing (b) using MATLAB
software. Cell nuclei are highlighted in blue and connective stroma in
pink.
This threshold was constant for all patients to reduce subjectivity bias. An
automated estimation of CD was obtained by measuring the number of nuclei
over a square unit of tissue. MR images were then analysed using an
Advantage Windows Workstation (GE Medical System), operating at 4.2-03
software level and using the Functool software package. Regions of interest
(ROIs) were manually drawn around tumour and normal PZ on the DW
images using the whole mounted specimens as reference [Figure 41].
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Figure 41. a) Diffusion weighted image of the prostate showing area of
low signal intensity in the right PZ. b) ADC map demonstrating the low
diffusivity in the right PZ indicated by the blue pixels. c) The
corresponding H&E pathology slide showing the presence of tumour
area on the right PZ as marked.
Each pathologic slice was visually matched to a corresponding MR image
based on the location of the ejaculatory ducts, diameter of the prostate, any
identifiable benign hyperplastic nodules, and approximate distance from the
base or apex. To be considered a match, the tumour must be in the same
anterior or posterior half of the prostate and at the same level from the
superior to inferior aspect of the gland. In difficult cases, pathology slices
were cross-referenced with T2 weighted images to identify the most accurate
location of the malignant lesion. The ROIs were the transferred on to the DW
images matching the same level and position of the chosen T2 weighted
slice. A researcher with at least 7 years experience in prostate MRI, and
myself with two years experience in prostate MRI drew all ROIs by
consensus. The ADC maps were automatically constructed on a pixel-by-
pixel basis and ADC values for each ROI were generated utilizing the MR
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manufacturer software (Functool). ADC values were then correlated with the
CD of the corresponding ROI on H&E stained slides.
Statistical analysis was performed using SPSS for windows (version 13.0).
The Kolmogorov-Smirnov test was used to demonstrate deviation from the
normal distribution. A paired t test was used to determine the statistical
differences between normal PZ tissue and tumour ADC values and between
the mean values for CD obtained from the five histological areas of both
normal PZ and tumour examined. The Pearson’s test was utilized to identify
any correlation between ADC and CD values. Receiver operating
characteristic (ROC) analysis was employed to assess the different ADC
cutoff values for prostatic cancer in the PZ.
4.3. Results
Thirty two patients were included in the trial analysis. One case showed
extensive infiltration of the gland by cancer which did not spare any normal
PZ area for ADC calculation. In this case only the data from tumour ADC and
CD were employed.
The mean, standard deviation, and range of ADC and CD values for tumour
and normal PZ regions are presented in Table 25.
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Mean SD Minimum Maximum
Tumour ADC (x10-3 mm2 /s) 1.45 0.27 0.78 2.08
PZ ADC (x10-3 mm2 /s) 1.90 0.33 1.37 2.77
Tumour CD (%) 18.89 4.93 10.70 28.42
PZ CD (%) 9.22 3.23 2.12 14.28
Table 25. The mean values for tumour and PZ ADC and CD are shown.
Tumour regions have lower ADC and higher cell density.
The calculated ADC values for cancer and normal PZ were consistent with
those previously reported in the literature. ADC values were significantly
lower (p < 0.001) in regions pathologically determined to be tumour
(1.45±0.27 x10-3 mm2/s) compared to regions assigned as normal peripheral
zone tissue (1.90±0.33 x10-3 mm2/s), with a mean difference of 0.45 x10-3
mm2/s (CI: 0.36-0.53). Similarly, the average cell density over the 5 fields
was significantly higher (p < 0.001) in tumour compared to normal peripheral
zone tissue (18.89±4.93% vs. 9.22±3.23%), with a mean difference of 9.67%
(CI: 7.84-11.50). Figure 42 demonstrates the ADC and cell density results for
all patients.
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Figure 42 Boxplot showing the differences in mean CD and ADC between the PZ and cancer areas. There is a degree of
overlap between the 2 tissues.
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Despite the overlap between the two tissue types, all cancer lesions had
lower ADC value and higher cell density compared to normal PZ within the
same gland [Figure 43].
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Figure 43. The differences in ADC values and cell density between tumour and normal PZ for all cases. Although there is a
noticeable overlap in values between individuals, all cancer lesions demonstrated lower ADC values and higher CD values
than normal PZ tissue.
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If a cutoff value of 1.62 x10-3 mm2/s based on the ROC curve for ADC values
is used, the resulting sensitivity and specificity for malignancy are 81% and
78% respectively. The area under the curve for diagnosing cancer, based
solely on the ADC value, was 0.86 giving a predictive value for cancer of
0.71. [Figure 44].
Figure 44. The blue line shows the ROC curve for ADC data. The AUC
for tumour detection accuracy is 0.86.
There was a highly significant correlation between the ADC values and CD (r
= -0.50, p < 0.0001) regardless of tissue type. The scatter plot in Figure 45
shows reduced ADC values from tissue demonstrating increased CD values.
Furthermore, high CD values were seen in malignant lesions which had lower
ADC values compared to normal PZ.
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Figure 45. Scatter plot of the estimated CD (expressed as a percentage
of surface area occupied by nuclei per high power field) with ADC
value. A significant correlation (p < 0.0001) is obtained between the
ADC value and the percentage CD for both tissue types (normal PZ and
tumour).
Although there is a statistically significant correlation between tumour ADC
and PSA (r = -0.40, p =0.024), of note no significant correlation was noted
between CD and PSA (r = 0.12, p = 0.49). Similarly Gleason score did not
correlate with neither ADC nor CD (r = -0.28, p =0.115 and r = -0.03, p
=0.84). By assessing the primary Gleason grade (as the most common
pattern of cancer cells in the studied lesions) there was a moderate negative
correlation with ADC (r= -0.335), but this did not achieve statistical
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significance (p= 0.061). A poor correlation was noted between Gleason
grade and CD (r= 0.057, p= 0.758). This limited correlation is possibly due to
the small range of Gleason scores with the majority of cases (71.8%)
recorded as Gleason 7.
4.4. Discussion
The extensive ductal structure of the normal prostate compared with the
highly restricted intracellular and interstitial spaces encountered in prostate
cancer, produces substantial differences in water diffusivity and thus the
potential for high image contrast using DWI.
There have been several studies at 1.5 Tesla reporting statistical differences
in ADC between prostate tissue types, especially between malignant lesions
and normal peripheral zone [119, 123, 143, 144]. Ren et al [145]
demonstrated significant differences in ADC values between normal prostatic
tissue in volunteers and prostatic diseases including prostate cysts, BPH and
prostate cancer. They suggested the use of this technique in the differential
diagnosis of prostatic diseases.
In general, ADC values have been found to be significantly lower in
malignant compared with non-malignant prostate tissue, leading to an
improvement in tumour detection and identification, compared with T2
weighted imaging alone, with sensitivity and specificity values of 50% and
79.6% respectively for T2w alone, versus 73.2% and 80.8% for combined
DWI and T2w imaging [146]. With advances in MR gradient coils, single shot
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echo planar imaging (EPI) has emerged as the technique of choice for
diffusion measurements in the prostate providing better resolution ADC
images [125]. A study by Issa et al [126] using EPI DW imaging also showed
statistical differences in ADC values between normal PZ, BPH and
cancerous prostatic regions.
However, at 1.5 Tesla, the signal-to-noise ratio (SNR) is intrinsically low, and
DW image quality is relatively poor. With the advent of 3.0 Tesla clinical
scanners and improved receiver coils combined with parallel imaging, high
SNR with low distortion DW images can be obtained within reasonable scan
times. Consequently, the production of ADC maps of the prostate for clinical
purposes is even more viable. Recent studies showed substantial promise
using 3.0 Tesla diffusion imaging to differentiate between benign and
malignant prostate tissue [117, 118, 120, 121, 147].
ADC values were found to be significantly lower in tumour regions compare
to normal PZ [117, 118]. The criteria for a suspected malignancy on the ADC
map was the presence of a hypointense focus relative to adjacent normal
prostate tissue with or without comparison to T2 weighted images. This lacks
direct correlation with the gold standard of histopathology. Therefore,
researchers have used transrectal biopsy findings as a reference. The
diffusion images were divided into regions and labeled as malignant or
benign according to ADC values and compared with histology from biopsy
samples for statistical analysis [121, 144, 146, 148]. There are a few
disadvantages using this method: 1) the number of TRUS biopsies varies
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from patient to patient; 2) biopsy findings do not provide tumour mapping and
accurate localisation in relation to the whole prostate cannot be achieved;
and 3) registering the TRUS and ADC images is difficult and the two
procedures are often done by different clinicians. Recent reports have
achieved a better comparison by using the whole mounted pathology
specimen following radical prostatectomy. Mapping of tumour regions could
then be drawn and direct comparison with ADC map performed [120, 122].
By using a 3.0 Tesla magnetic field for superior signal and with reference to
whole mounted radical prostatectomy specimens, our results confirmed the
previously documented evidence that ADC measurement is useful in
differentiating normal PZ from malignant prostatic lesion. Most malignant
lesions (81%) showed ADC values lower than our arbitrary cutoff value of
1.62 x10-3 mm2/s [Figure 46].
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Figure 46. Using a cutoff ADC value of 1.62 x10-3 mm2/s, a good
separation is noted between tumour and normal PZ ADC values.
However, there was considerable overlap between ADC values of tumour
and normal PZ; this indicates that the use of ADC value alone for tissue
discrimination could result in misdiagnosis. It is recommended that
interpretation of ADC values be carried out in comparison with ADC values
for benign PZ in the same gland.
The increased cell proliferation in prostate cancer regions leads to the noted
increased cell density of 18.89% for malignant foci versus 9.22% for normal
PZ. As expected, the malignant tissue structure is compact with a loss of
interstitial space, resulting in the restricted diffusion, which led to lower ADC
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values in pathologically confirmed malignant lesions compared to normal PZ
(1.45 x10-3 mm2 /s vs 1.90 x10-3 mm2 /s).
The correlation between ADC and CD is of great importance and can lead to
future research. With reference to our results, we looked at CD as a
characteristic of cancer that is related to cell proliferation. Measuring ADC
values in suspected lesions pre-operatively can predict the CD, which may
then reflect the cancer aggressiveness. Highly cellular cancers have a
smaller interstitial space, hence a lower ADC. Through identification of the
areas of highest cellularity, it might be possible to predict cancer
aggressiveness. This will provide an additional diagnostic feature of
preoperative prostate MRI.
There are some limitations to our study. First, a relatively small number of
patients had no follow up data for PSA recurrence or cancer specific survival.
This needs to be addressed in future studies in which a 5 or 10 years follow-
up period would be required to identify any prognostic value of measuring
ADC preoperatively.
Second, there were some difficulties in registering the exact site of the
examined pathological lesion with the site of the ADC measurement, despite
the use of identifiable landmarks. This was mainly due to specimen shrinkage
and the different angulations, ranging between 10 to 20 degree, in which
pathology and MRI axial sections were obtained.
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Third, this study focused on the peripheral zone as it is the most common
location of cancer, however, minority of cancer are located in the transitional
zone and can be difficult to identify. In our cohort, three patients had both
transitional zone and peripheral zone cancers. The ROIs in these cases were
placed only in the peripheral zone lesions to obtain consistency of data and
reduce bias. The central gland has a different cellular structure (compact
fibromuscular stroma) compared to peripheral zone. It would be interesting to
see the results of ADC and CD in central gland tumour in a larger study.
4.5. Conclusion
Tumour cellularity has a significant impact on ADC values obtained from
malignant lesions and normal PZ. Differentiation between malignant lesions
and normal PZ with DWI and the prediction of CD may have an important
role in prostate cancer management.
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5. DESCRIPTION OF MR DERIVED ENHANCEMENT
PARAMETERS IN PATHOLOGICALLY CONFIRMED
PROSTATE CANCER AND NORMAL PERIPHERAL
ZONE REGIONS
5.1. Objective
Research into angiogenesis has produced mounting evidence that alterations
in microcirculation (blood circulation at capillary level) play an important role
in the pathogenesis of many neoplastic diseases [149]. Abnormal
angiogenesis is often accompanied by a change in physiological variables,
such as capillary permeability and increased blood flow. In prostate cancer,
studies have shown that microvessel density is an independent predictor
factor of pathological stage [150] and has a significant association with the
incidence of metastases [151]. A greater density of tumour vessels increases
the opportunity for tumour cells to enter the circulation and subsequently
develop metastases. Bettencourt et al [152] reported that microvascularity is
a prognostic marker allowing prediction of tumour recurrence in patients
undergoing radical prostatectomy.
Normally assessment of angiogenesis can be achieved only when pathologic
specimens are obtained. However, many investigators have been attempting
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to find reproducible, non-invasive, and quantitative methods of assessing
neovascularisation in cancer. Dynamic contrast-enhanced MRI (DCE MRI)
has been a promising diagnostic tool in the management of prostate cancer
through its ability to spatially map the microvascular density, blood flow and
permeability that is associated with malignant tumour growth [153-155].
Previous studies have analysed the signal intensity (SI) time curve utilising
multi-compartment physiological models. These demonstrate the altered
pharmacokinetic parameters in regions of increased enhancement due to
malignancy, with results obtained at both 1.5 and 3 Tesla [156-158].
However, these models are complicated to derive, require longer DCE-MRI
examination (more than 5 min) to allow the accumulation of contrast agent,
and require extensive post processing.
This study aims to identify the differences in enhancement parameters
between malignant prostatic lesions and normal peripheral zone (PZ), with
reference to whole mount histopathology specimens, using model-free simple
mathematical descriptions of SI time curves acquired using DCE-MRI at 3
Tesla.
5.2. Methods
5.2.1.Patients
Approval from the Local Ethics Committee was granted and written consent
obtained from all patients for their MR images to be used for research
purposes. Fifty two patients with biopsy proven prostate cancer were
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recruited from January 2005 to December 2007. They were referred from the
Urology Department for MR staging prior to radical prostatectomy. The mean
age was 63 years (42-71), mean PSA was 7.6 ng/ml (2.5 - 16 ng/ml),
Gleason score ranges from 6 to 9 with the majority of cases (61.5%) being
Gleason 7. The minimum interval between trans-rectal ultrasound guided
prostate biopsy and MR examination was six weeks to allow the inflammation
and haemorrhage following biopsy to resolve. None of the patients received
any treatment prior to MRI.
5.2.2.Image Acquisition
MRI was performed on a 3 Tesla scanner (Signa HDx, GE Healthcare,
Milwaukee, USA) using an eight-channel, torso phased array, receive only
coil. Patient preparation as discussed in chapter 3. After conventional T2-
weighted imaging, DCE-MRI was acquired axially using a 3D Fast Spoiled
Gradient Recalled (FSPGR) sequence (18 flip angle, field of view 30 x 30
cm, matrix 256 x 128, TR/TE 5.1/2.1 ms, parallel imaging factor of 2, slice
thickness 4-5 mm, temporal resolution 6.67 to 8.36 s per volume providing
700 to 800 images in 4:45 to 5:35 min). This was acquired immediately
before, during and after bolus administration of 0.1 mmol/kg body weight
Gadolinium-DTPA based contrast agent (Omniscan, GE Healthcare,
Amersham) delivered by power injector (Spectris Solaris, Medrad, Indianola,
Pennsylvania) at a rate of 3 ml/s, followed by 20 mls of normal saline. All MR
images were analysed using a dynamic image viewing and analysis
programme (XDIVA) developed using IDL (ITT Visual Information Solution,
Boulder, Colorado).
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5.2.3.Histological study
Patients proceeded to radical retropubic prostatectomy as the sole radical
treatment. Prostatectomy specimens were prepared and examined as
described in chapter 3. An experienced consultant pathologist outlined
regions of tumour on the H&E slides.
5.2.4.Histology and DCE-MRI correlation
Regions of interest (ROIs) were manually drawn around tumour and normal
PZ on the DCE images using the whole mounted specimens as reference
[Figure 47].
Figure 47. The cancer regions are outlined on the H&E stained
pathology slide of the whole mounted prostatectomy specimen (left). T2
weighted image shows a low signal intensity area in the right peripheral
zone (middle). The positive enhancement integral image (right) shows
the corresponding area of tumour (outlined in red) and an area of
normal peripheral zone (outlined in grey). The high contrast uptake
seen in the central gland on the positive enhancement integral image
reflects the presence of hypervascular benign prostatic hypertrophy in
most cases.
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Each pathologic slice was visually matched to a corresponding MR image
based on the location of the ejaculatory ducts, the diameter of the prostate,
any identifiable benign hyperplastic nodules, and approximate distance from
the base or apex. To be considered a match, the tumour must be in the same
anterior or posterior half of the prostate and at the same level from the
superior to inferior aspect of the gland. When only one cancer area was
identified a similar sized area of normal PZ area was outlined. However,
when more than one malignant lesion was identified in the prostate, equal
numbers of normal PZ regions were assigned to facilitate statistical
comparison. There were potentially some difficulties in registering the site of
the examined pathological lesion with the site of the DCE measurement
despite the use of identifiable landmarks. This was mainly due to specimen
shrinkage and small differences in angulations ranging between 10 and 20
degrees, in which pathology and MRI axial sections were obtained.
5.2.5.Data analysis
The DCE MR images were used to automatically construct a “positive
enhancement integral” map on a pixel-by-pixel basis. The XDIVA application
was then used to outline ROIs in tumour and normal PZ, and to construct the
SI-time curve. The point where the contrast reaches the prostate gland and
causes the SI to begin to rise was visually marked on the SI-time curve. The
application then automatically extracts parameters to measure changes in
Enhancement Index (EI) over time for each ROI drawn on DCE images
[figure 48], where Enhancement Index is defined as (SIt/SI0) - 1.
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Figure 48. Signal intensity time curve for a typical malignant lesion
(type 3 curve). X-axis shows time in seconds, and y-axis shows signal
intensity (arbitrary unit). This illustrates the time when the contrast
reached the prostate (a), maximum enhancement achieved (b), the time
to maximum enhancement (b-a), initial and final slopes.
These enhancement parameters included the following:
Maximum Enhancement Index (MaxEI) was defined as the peak EI during
the dynamic examination. Time to maximum (Tmax) was defined as the time
taken for the EI to reach this maximum (MaxEI), taking the point where the
contrast reaches the prostate as zero (point a in figure 48). Enhancement
Index at 30s (EI30) was defined as the fractional rise in signal at 30s
compared to the initial pre-contrast signal. Initial slope was defined as the
fractional change in signal per minute (1/min) following initial enhancement.
This reflects the wash-in phase. Final slope was defined as the fractional
change in signal per minute (1/min) for the final 2 minutes of the EI time
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curve. This reflects the wash-out phase. The area under curve was defined
as the integral of fractional enhancement over the first 4 minutes of contrast
uptake following initial enhancement, and was corrected for differences in
temporal resolution. The 4 minute period reflects the shortest acquisition time
for the DCE-MRI series used in the study. Acquisition time changes were
necessary due to scanner software upgrades and protocol development.
The types of SI time curves were described as: type 1, when SI increases
with no subsequent decrease or leveling; type 2 when SI increases to a peak
then levels off; and type 3 when SI increases rapidly and then decreases
after a peak [Figure 49].
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Figure 49. Types of SI time curve: Type 1 curve demonstrates slow SI
rise with no subsequent washout (top); type 2 curve demonstrates
rapid rise in SI and subsequent plateau with no rapid washout (middle);
type 3 curve demonstrates rapid uptake in SI and rapid washout
(bottom).
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Statistical analysis was performed using SPSS (version 13.0, SPSS Inc.,
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to demonstrate
deviation from the normal distribution. A paired t-test was used to evaluate
the statistical differences between PZ and tumour DCE parameters. Chi-
square test was employed to test the difference in curve types. Receiver
operating characteristic (ROC) analysis was employed to 50 ROIs (randomly
selected 25 lesions and 25 normal PZ ROIs) to assess the different DCE
parameter cut-off values for prostatic cancer in the PZ. These cut-off values
were then used to test the sensitivity, specificity, positive predictive value,
negative predictive value for the remaining 90 ROIs. Logistic regression
analysis was utilized to identify the sensitivity and specificity of combined
DCE parameters in identifying prostate cancer. Confidence intervals (CI) for
ratios were calculated using the following formula as described by Gardner
and Altman [159]:
p – (N1-/2 x SE) to p + (N1-/2 x SE),
Where p is the observed proportion of subjects, N1-/2 is the appropriate value
from the standard normal distribution for the 100(1-α/2) percentile, SE is the
standard error. For a 95% CI N1-/2 = 1.96.
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5.3. Results
Seventy malignant lesions were identified in 52 patients and were compared
with 70 regions of normal PZ. Table 24 demonstrates the differences in DCE-
MRI parameters between malignant lesions and normal PZ.
Parameters Region
Cancer lesion Normal PZ P value
MaxEI (a.u.)* 2.71 ± 1.09 1.74 ± 0.70 <0.0001
TMax (min) 2.04 ± 0.91 3.30 ± 0.66 <0.0001
EI at 30s (a.u.) 2.22 ± 1.04 1.04 ± 0.51 <0.0001
Initial slope (1/min) 4.44 ± 2.08 2.08 ± 1.03 <0.0001
Final slope (1/min) -0.07 ± 0.14 0.08 ± 0.13 <0.0001
nAUC (a.u.) 9.34 ± 3.84 5.44 ± 2.17 <0.0001
*a.u. (arbitrary unit)
Table 26. Mean ± standard deviation values for all DCE parameters for
cancer lesions and normal PZ. Statistically significant p value when
tested utilizing paired T-test.
Malignant prostatic lesions had a 56% higher MaxEI compared to normal PZ
and took nearly half the time to reach that maximum (p<0.0001). Hence, at
30s, cancer lesions had double the EI compared to normal PZ. Similarly, the
wash-in rate as represented by the initial slope was much higher in cancer
lesions compared to normal PZ (4.44 ± 2.08/min versus 2.08 ± 1.03/min).
Whilst the wash out rate, characterised by the final slope, was -0.07/min for
the cancer lesions (the negative value representing the reduction in signal
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during the washout phase) that for normal PZ was 0.08/min. The area under
the SI time curve was 72% higher in malignant lesions compared to normal
PZ. This signifies the increased quantity of contrast accumulated as a
consequence of changes in extracellular extravascular space, vessel
permeability and perfusion.
ROC analysis was performed on a randomly selected set of 25 pairs of
cancer and normal PZ ROIs to select cut-off values which were then used to
assess the sensitivity, specificity and accuracy for each parameter
individually for the remaining 45 pairs. The cut-off values for MaxEI, Tmax,
EI30s, initial slope, final slope and nAUC were 1.93, 3.02min, 1.30, 2.59/min,
0.12/min, and 6 respectively. The ROI was labeled “malignant” if the value for
the parameter was above the given cut-off values for MaxEI, ET30s, initial
slope and nAUC and below the cut-off values for Tmax and final slope. Using
these cut-off values, the most effective parameters were the EI30s and the
initial slope with sensitivity of 87% and specificity of 76% as shown in Table
27.
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AUC Chosencut-off
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
MaxEI 0.80 1.93 82 (71 -93)
72 (56 -
85)
74 (62 -
86)
80 (68
- 92)
77 (68 -
85)
Tmax 0.89 3.02 84 (73 -95)
76 (64 -
88)
77 (65 -
88)
83 (71
- 94)
80 (72 -
88)
EI
(30s) 0.91 1.29
87 (77 -
97)
76 (74 -
92)
78 (67 -
89)
85 (74
- 96)
81 (73 -
89)
Initial
slope 0.91 2.59
87 (77 -
97)
76 (74 -
92)
78 (67 -
89)
85 (74
- 96)
81 (73 -
89)
Final
slope 0.76 0.12
73 (60 -
86)
74 (61 -
87)
74 (61 -
87)
73 (60
- 86)
74 (65 -
83)
nAUC 0.85 6.00 87 (77 -97)
67 (53 -
80)
72 (59 -
85)
83 (71
- 95)
77 (68 -
85)
Table 27. AUC values for all enhancement parameters with the resulted
sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV) and accuracy for tumour identification based on
the pre-determined cut-off values. 95% confidence intervals are shown
in parenthesis. (MaxEI: maximum enhancement index (arbitrary unit); TMax:
time to maximum enhancement (in minutes); EI: enhancement index
(arbitrary unit); Initial and final slopes (arbitrary unit); nAUC :normalised area
under SI-time curve (arbitrary unit))
A combination of parameters proved even more powerful as demonstrated by
logistic regression analysis. The resulting sensitivity, specificity, positive
predictive value, negative predictive value and accuracy for the combined
DCE-MRI data are detailed in Table 28. This shows a good sensitivity of 89%
and specificity of 90%. The only parameters that contributed significantly to
the logistic regression model were MaxEI, Tmax and the area under SI time
curve. After excluding the other parameters, there was no significant change
in results, with a sensitivity of 89%, and specificity of 91%.
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LRA
parameters
Sensitivity
(%)
Specificity
(%)
PPV (%) NPV (%) Accuracy
(%)
All
parameters
89 (81 –
96)
90 (83 –
97)
90 (83 –
97)
89 (81 –
96)
89 (84 –
94)
Only
significant
parameters
89 (82 –
96)
91 (84 –
98)
91 (85 –
98)
89 (81 –
96)
90 (85 –
95)
Table 28. Logistic regression analysis results including all
enhancement parameters (2nd row) and after excluding the non-
significant parameters (3rd row). 95% confidence intervals are shown in
parenthesis.
By looking only at the types of SI time curve, the following results are
obtained: in the cancer group, 24 cases were type 3, 39 cases were type 2,
and seven cases were type 1. Whereas in the normal PZ group, none of the
cases were type 3, 25 cases were type 2, and 45 cases were type 1 (Chi-
square test = 18.05, p <0.0001). Significant overlap in type 2 curve is noted.
These are the difficult cases that require a better way to separate lesions
from normal PZ. When selecting only cases with type 2 curve (39 tumour and
25 normal PZ), the difference in enhancement parameters remains highly
significant (Table 29).
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Parameters Region
Cancer lesion Normal PZ P value *
MaxEI 2.91 ± 1.34 1.86 ± 0.81 <0.0001
TMax (min) 1.87 ± 0.81 2.88 ± 0.78 <0.0001
EI 30 2.43 ± 1.24 1.36 ± 0.64 <0.0001
Initial slope (/min) 4.86 ± 2.48 2.72 ± 1.27 <0.0001
Final slope (/min) -0.06 ± 1.55 0.03 ± 0.13 =0.009
nAUC 10.08 ± 4.70 6.17 ± 2.66 <0.0001
(* Paired T test.)
Table 29. By selecting cases with type 2 SI time curves only, the mean ±
standard deviation values for all DCE parameters in cancer lesions and
normal PZ remains statistically significant. A paired T-test was used to
evaluate differences.
Employing the logistic regression model, with only the significant parameters
(MaxEI, Tmax, AUC) included for type 2 curve cases, showed high
sensitivity, specificity, positive predictive value, negative predictive value and
accuracy for tumour identification: 90% (95% CI= 80% to 99%), 84% (95%
CI= 70% to 98%), 90% (95% CI= 80% to 99%), 84% (95% CI= 70% to 98%)
and 88% (95% CI= 79% to 96%) respectively. This allows identification of
malignant lesions even though they demonstrate type 2 curve pattern.
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5.4. Discussion
With the introduction of Gadolinium contrast agent, advances in MR
sequences with improvements in spatial and temporal resolution, DCE-MRI
has become commonly used in the evaluation of prostate cancer. Alonzi et al
[153] reviewed the use of dynamic imaging in prostate cancer and
demonstrated an improvement in sensitivity, specificity and accuracy in
cancer localisation and staging, compared to T2-weighted imaging alone.
Jager et al [160] reported improvement in tumour localisation mainly based
on enhanced sensitivity of DCE-MRI compared to T2 weighted imaging
(73.5% versus 57.5% respectively).
Several studies [111, 161, 162] have shown that, after giving a gadolinium-
based contrast agent, prostate cancer enhances earlier and washes out
faster than normal PZ. Liney et al [163], in a study of 12 patients, reported a
shorter time to reach maximum enhancement in suspected prostate cancer
lesions compared to normal PZ (2.48 min versus 3.74 min). Padhani et al
[164] showed a significant difference in signal intensity parameters between
normal PZ and tumour, but there was no direct histological correlation. Other
studies at 1.5 Tesla [111, 161, 162, 165] have used whole mount
prostatectomy specimens as a standard reference to correlate with regions of
interest (ROI) co-registered on DCE images obtained preoperatively.
Significant differences in various DCE parameters were noted between
cancer and normal PZ regions.
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To our knowledge, this study is the first to evaluate simple model free
enhancement parameters at 3 Tesla using whole mount radical
prostatectomy specimens as reference. At 3 Tesla, compared to 1.5 Tesla,
there is a doubling of the signal-to-noise ratio which can be used to improve
spatial resolution and, by employing parallel imaging techniques, the
temporal resolution of the MR measurements can also be significantly
improved. The superior temporal resolution for any given region of interest
provides better delineation of changes in tissue signal intensity observed
during contrast administration.
During the dynamic series of our study, we noted that contrast reaches the
prostate gland in 24-28 seconds. This depends on several factors such as
cardiac output and the vascularity of the prostate. Measuring the
enhancement parameters from the time the contrast reaches the prostate
(position a in Figure 48), rather from the time of contract injection, gives
consistency to the obtained data and reduces bias.
Alternative approaches exist to analyse data obtained by DCE-MRI. Fully
quantitative kinetic parameters can be derived from concentration-time
curves that are mathematically fit using one of a number of recognised
pharmacokinetic models. These models require knowledge of native tissue
T1 and the arterial input function, both of which can be variable and subject to
significant errors. The approach chosen here, whereby the evaluated
parameters are model free indices (often called semi-quantitative) that
describe tissue enhancement using a number of simple descriptors, reflects
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the clinical requirements of radiologists to make a diagnostic decision. These
model free parameters are relatively straightforward to calculate; they do
however, have some limitations including the fact that they may not
accurately reflect the changing contrast medium concentration in tissue.
The maximum enhancement during the early phase of DCE-MRI was earlier
and higher in prostate cancer lesions compared to normal PZ. This reflects
the increase in vascular perfusion and the accumulation of contrast agent in
cancer lesions. However,.this measurement is not consistent in cases where
the enhancement continues to increase or remains relatively constant
throughout the experiment time (4 minutes in this study), as the time to
maximum enhancement can only give a correct value if the studied signal
reaches its maximum enhancement before the end of the experiment. This
should be interpreted with caution. Moreover, our algorithm uses a strictly
numeric search and does not take into account any noise spikes which may
occur following the change of the curve from maximum upslope to a more flat
slope. Improvement to the algorithm need to be addressed in future studies.
This includes filtering out the noise spikes and the use of the initial 90% of
max enhancement of Noworolski [166].
The initial slope reflects the degree of early enhancement in the tissue. The
increase in signal enhancement does not derive from the contrast agent in
the blood vessels only, but from the accumulation of contrast in the interstitial
space. The initial slope reflects mostly the vascular permeability and the size
of interstitial space. We determined the initial slope from the time between
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the contrast reaching the prostate (start of the signal intensity rise) and the
30s time point. This was in line with the reports of other studies, which found
that DCE scanning window between 30s and 60s after contrast injection
allows a good depiction of cancer within PZ [162, 165].
Delayed imaging obtained 3-4 min after injection is useful to appreciate the
wash-out phase of the contrast agent and helps to discriminate cancer form
normal PZ. In agreement with the results of other studies [162, 167], we
found that contrast wash-out was significantly more prominent in cancer than
in normal PZ, as determined by the negative final slope (-0.067 versus 0.088
/min). This reflects the increased vascular permeability and /or increase
vasculature surface area in cancers as the increased concentration of
contrast in the interstitial space leaks back into the vasculature and drains
out from the cancer lesions more rapidly than from normal tissue.
The shape of the SI time curve provides additional information. Although
there is a degree of overlap between cancer and normal PZ curves, all type 3
curves were related to cancerous lesions, whereas 86.5% of type 1 curves
were related to normal PZ. The difficulty arises in evaluating cases with a
type 2 curve, since there is a considerable overlap between the two tissue
types. However, by evaluating the SI time curve parameters, highly
significant differences between tumour and normal PZ regions could be
achieved with good sensitivity and specificity. This suggests that a simple
visual assessment of DCE-MRI based on the curve shape may not
differentiate between malignant and normal enhancing tissues leading to low
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diagnostic accuracy. Further assessment using this simple technique may
lead to a better result for tumour identification.
This semi-quantitive assessment of DCE parameters may have an important
role not only in tumour localisation, but also in assessment of prostate cancer
response to anti-androgen therapy. Padhani et al [168] have assessed the
effects of hormone treatment on vascular permeability, as evaluated by DCE-
MRI, and have shown a significant reduction in tumour permeability following
androgen deprivation.
There are some limitations to the use of MRI in prostate cancer patients. Post
biopsy haemorrhage leads to artefacts which are known to interfere with MR
image interpretation and result in overestimation of tumour volume. Previous
studies [169, 170] have recommended deferring an MRI examination for at
least 3 weeks after biopsy, to obtain more reliable tumour localisation and
staging accuracy. We deferred all MR examinations for 6 weeks, which was
adequate to obtain good quality images in our cohort of patients.
We failed to identify any significant correlation between the DCE-MRI
parameters and PSA or Gleason score. This is in line with previous reports
[160, 164]. A correlation between enhancement parameters and Gleason
score may have been expected, since the latter has been shown to correlate
with microvessel density measurement [171]. However, the lack of correlation
seen may be explained by selection bias in our series, as the majority of
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patients (88.4%) undergoing radical prostatectomy for potentially organ
confined disease had either Gleason 6 or 7.
We did not study the enhancement patterns of prostatitis or central gland
benign prostatic hypertrophy (BPH) lesions. Previous reports failed to
establish a significant difference in enhancement pattern between BPH and
cancer lesions [153, 162, 164]. Also, you would expect that prostatitis can
cause increased vascularity and permeability due to the release of
inflammatory factors, however, the features of DCE-MRI in prostatitis have
not been published in peer reviewed journal. Therefore, the accuracy of
DCE-MRI in detecting cancers in central gland or in the presence of
prostatitis remains to be determined.
5.5. Conclusion:
DCE-MRI is a simple, quick technique which allows evaluation of malignant
lesions based on their abnormal vascular features. The significant differences
in DCE-MRI parameters between cancer and normal areas can improve the
localisation of tumour foci, which may have many potential uses including
directing prostate biopsy or targeting cancer lesions for minimal invasive
treatment.
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6. THE POTENTIAL ROLE OF 3 TESLA MRI IN
PATIENTS WITH RISING PSA BUT NEGATIVE
PROSTATIC BIOPSIES
6.1. Introduction
The management of patients with a persistently increasing serum prostate
specific antigen (PSA) level and negative prostatic biopsies can be difficult,
debatable and represents a great diagnostic challenge to urologists.
Patients with a negative first set of trans rectal ultrasound-guided (TRUS)
biopsies often undergo multiple repeated biopsies, prompted by the presence
of atypical suspicious cells in the first biopsy, rising PSA and/or abnormal
digital rectal examination [105]. The reported detection rate of malignancy in
the second set of biopsies is 10-23% [172, 173] but can be up to 41% when
more than two sets of biopsies were performed [174]. The European Prostate
Cancer Detection Study [172] reported their findings in a cohort of 1051 men
with PSA values between 4.0 and 10.0 ng/mL. After an initial cancer
detection rate of 22% with sextant biopsy, their subsequent positive biopsy
rates were 10%, 5% and 4% for the second, third and forth attempts
respectively. Researchers have also examined the role of extended,
repeated biopsy (saturation biopsy) when approximately 20 biopsies are
done under general anaesthetics. Stewart et al [175] performed saturation
biopsies in 224 men in whom previous negative biopsies had been reported.
161
Cancer was detected in 34% of patients, of which 68% warranted radical
prostatectomy. In a recent study a group from Leicester [176], assessed a
standardized 36 core template-assisted transperineal prostate biopsy
technique in 40 patients with elevated PSA and previous multiple prostate
biopsies. They detected prostate cancer in 68% of patients, with Gleason
score ranges from 6 to 9. They concluded that the technique is safe and
effective and should be considered in this cohort of patients.
The reported data detailed above shows the lack of sensitivity of TRUS for
detecting prostate cancer. Due to the high false negative rate of TRUS
biopsy, a more reliable imaging modality to detect prostate cancer and direct
prostatic biopsy is needed. Although MRI has been used mainly for
localisation and staging of biopsy proven prostate cancer, a few studies have
focused on the role of MRI in patients with previously negative TRUS biopsy
[177-180]. Researchers have used various sequences, with a wide variation
in the reported sensitivity and specificity [181].
In this study, the role of MRI at our centre in the assessment of patients with
rising PSA and previous negative TRUS biopsy, using dynamic contrast
enhancement and endorectal imaging is evaluated.
6.2. Methods
6.2.1.Patients recruitment
This was a prospective, single arm, consecutive patient study. Ethical and
trust approval was obtained prior to recruitment. The protocol was reviewed
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by two external referees. Inclusion criteria were patients who were
considered for repeat TRUS biopsy, on the basis of abnormal clinical
examination, persistent PSA elevation or the presence of suspicious cells on
previous biopsies. Exclusion criteria were contraindications to MRI. The
patient information leaflet was reviewed by the local Research Consumer
Panel and validated. Patients were invited to enter the study and were given
the information leaflet at least 7 days prior to MRI scanning to allow sufficient
time to make an informed decision about participation. Formal consent was
obtained from all patients.
Twelve patients were included in the study with ages ranging from 60 to 72
years and a mean age of 65.7. The mean PSA value was 7.6 ng/mL, ranging
from 4.2 to 16 ng/mL. All patients had at least one previous set of TRUS
biopsies which were negative for malignancy. Time from the most recent set
of TRUS biopsies to study entry ranged from 4 to 100 weeks (median 22
weeks). The indication for repeat TRUS biopsy was persistently elevated
PSA value in 7 patients and the presence of suspicious cells on initial biopsy
in 5 patients.
6.2.2.MR examination
MR preparation, parameters for T2 weighted and DCE-MRI and the use of
endorectal coil imaging have already been described in Chapter 3. All studies
were read by 2 clinicians in consensus (one MR radiologist and one research
fellow in prostate MRI). In each image, the prostate gland was assessed for
tumour involvement. Suspicious areas were localised by assigning them into
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posterior/ anterior, lateral/ medial, base/ mid/ apex and left/ right sectors. The
MR information was based on the combined data from T2 weighted imaging
and DCE-MRI and were formally reported by an experienced MR radiologist.
The images were classified as normal or suspicious based on areas of low
signal intensity on T2 weighted imaging and/or areas of increased contrast
uptake on DCE-MRI. Images were then saved onto CD for subsequent use in
directing TRUS biopsy [Figure 50].
Figure 50. Suspicious area of low signal intensity seen in the right
postero-medial PZ on T2 weighted imaging using PPA (left) and ER
coils (middle). This correlates with an area (shown in red) of increased
contrast uptake seen on DCE-MRI (right).
6.2.3.TRUS biopsy
This was performed within a week following the MRI. All biopsies were
performed by a single experienced radiologist. Standard preparation was
followed (quinilone and metronidazole antibiotic prophylaxis and enema
administration). A Phillips ultrasound machine (Phillips iU22) with transrectal
probe (C9.5 EC) was used. Patients were scanned in the left lateral
decubitus position with knees and hips flexed to 90 degrees. Ultrasound
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assessment of the prostate was done in both axial and sagittal planes [Figure
51]; biopsies were performed in the axial plane.
Figure 51. Trans-rectal ultrasound scan. Axial view on the left and
sagittal view on the right. This allows measurement of the prostate
gland in 3 dimensions to get the prostatic volume.
Local anaesthesia of the prostate was achieved using Lidocaine infiltration
around the nerves bundles. Prostatic cores were obtained using an 18 gauge
biopsy needle with a spring loaded biopsy gun (Manan gun, MANNAN
Medical Products, Inc). A 12 core biopsy scheme was employed [Figure 52]
including one targeted biopsy from the area that had suspicious changes on
MR imaging.
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Figure 52. 12 core biopsy scheme. This was adjusted to include one
biopsy from the suspicious area detected on MR imaging.
The number of biopsies remained the same (12 cores) as per routine clinical
practice to prevent detection bias, as a higher number of biopsies will lead to
a higher detection rate. The suspicious areas were identified by carefully
evaluating the MR images while slicing the TRUS image from the prostate
base to the apex axially and from the urethra to the left or right laterally
[Figure 53]. The targeted biopsy was labelled and sent in a separate pot for
histological examination.
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Figure 53. Hypoechoic lesion imaged during TRUS in an area highly
suspicious of cancer on MRI (white arrow). Biopsy revealed
adenocarcinoma.
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6.3. Results
Seven (58.3%) prostate cancers were diagnosed in the 12 patients recruited
(5 cases with Gleason score of 3+3=6, and 2 cases with Gleason score of
3+4=7. ASAP had previously been diagnosed in 4/7 of these patients. As
shown in Table 30, MRI identified suspicious areas consistent with
malignancy in 11 cases. Out of these cases, biopsy showed cancer presence
in 7 cases. However, the site of positive biopsy correlated correctly with the
exact area of suspicion on MRI in 3 cases (27.2%) only. For the remaining 4
cases, 3 cases showed cancer in the same side as the suspicious MRI
findings, but in one case the cancer was on the side contra-lateral to the MRI
lesion (patient number 1).
Patient
number
Site of
MRI lesion
Pathological
evidence of
cancer
Site of
cancer on
biopsy
Pathological
features of MRI
focus
1 Right Positive Left Normal
2 Left Negative - Normal
3 Left Positive Left Cancer
4 Right Positive Right Cancer
5 Right Positive Right Inflammation
6 Left Negative - Inflammation
7 Right Negative - Inflammation
8 Left Negative - Inflammation
9 Right Positive Right Cancer
10 Negative Negative - Normal
11 Right Positive Right Normal
12 Left Positive Left Normal
Table 30. This shows the site of suspicious lesion on MRI, if cancer was
detected in this biopsy round, its site and pathological findings for the
suspicious MRI focus for each patient.
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Out of the 11 cases with suspicious MRI findings, 4 cases showed active,
high degree of inflammation with several acini filled with neutrophil
polymorphs and the formation of microabscesses within the targeted
biopsies, but with no evidence of cancer in the gland.
Although the suspicious MRI site was shown to be pathologically normal in 4
cases, cancer was detected in other areas of the gland in 3 cases [Figure
54].
Figure 54. Organisation chart detailing all the pathological findings for
the suspicious MR lesions.
6.4. Discussion
Despite the advances in our understanding of PSA and its use to indicate
TRUS biopsy, the prostate cancer detection rate for sextant biopsy remains
low [172]. Therefore, further biopsies are often indicated in cases of
persistent elevation of PSA or in the presence of ASAP. Eight, twelve and
even saturation biopsies have been performed to improve the detection rate.
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The detection of ASAP on the initial biopsy warrants further investigations
due to its strong association with prostate cancer [182]. Cancer is found on
subsequent biopsies after the initial diagnosis of ASAP in 55% of cases [51],
which indicates that a ASAP diagnosis mandates immediate re-biopsy.
Investigators have attempted to detect prostate cancer prior to biopsy using
transrectal ultrasound scanning. Although cancer was detected in 30% of
patients with a hypoechoic lesion, 18% of men with a normal TRUS had
prostate cancer and as many cancers were isoechoic as were hypoechoic
[183]. Consequently, researchers have studied the role of MRI in this group
of patients to detect suspicious foci to be targeted for biopsy [176-181, 184].
The aim is to diagnose cancer earlier and prevent further unnecessary
biopsies with their associated morbidity and complications.
In a study performed by Perotti et al [179], MR imaging with the use of an
endorectal coil had encouraging results for the detection of tumour foci in
patients who had elevated PSA levels and negative TRUS biopsy. In their
study, endorectal MRI had 85.7% sensitivity and 65.4% specificity for
detecting malignant lesions. The site of positive biopsy correlated correctly
with the area of suspicion on MRI in 85.7% of cases.
In another study performed by Beyersdorff et al [178], combined endorectal
and phased-array body coil technique was used. They achieved a similar
sensitivity and specificity to Perotti et al. However, a site-by-site analysis
170
failed to show a significant correlation between MR imaging and individual
biopsy site findings.
The use of MR spectroscopy has also been investigated in patients with prior
negative biopsy in order to improve cancer detection rate on subsequent
biopsy. In general, authors reported good and promising results to warrant
the routine clinical use of MRI in this group of patients [Table 31].
Pt
No
SEN
(%)
SPEC
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Bhatia et al 21 100 84 40 100 86
Amsellem-
Ouazana et al
42 73 96 92 87 88
Prando et al 42 100 44 55 100 67
Yuen et al 24 100 71 58 100 79
Table 31. A review of papers on the use of MR spectroscopy in patients
with prior negative biopsy. (Patient number (Pt No), Sensitivity (SEN),
Specificity (SPEC), Positive predictive value (PPV), Negative predictive
value (NPV), Accuracy (ACC)).
In the Yuen et al study [180], MR spectroscopy increased the sensitivity and
NPV of prostate cancer detection from 57% to 100% and from 83% to 100%
respectively. However, the specificity and PPV decreased from 88% to 71%
and 67% to 58% respectively.
The study described in this chapter is unique as it assesses the role of DCE-
MRI for the detection of cancer foci in the prostate prior to repeat biopsy.
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DCE-MRI has the potential to image the increased vascularity seen in
cancers and hence improve localisation and detection based on the
abnormal vascular morphology. It has been reported to increase the
sensitivity and specificity for tumour detection compared to T2 weighted
imaging [185].
This study showed that combined T2 weighted and DCE-MRI detected
cancer within the same prostatic lobe in 7 out of 11 cases. However, there
was a poor anatomical correlation between the area positive for malignancy
on biopsy and the suspicious region on MRI (3 out of 11). A possible
explanation for this finding is the difficulty in ensuring the accuracy of
targeting of the TRUS guided biopsy to suspicious areas seen on MRI. The
sampled area may not have correlated with the area intended for sampling.
This spatial accuracy cannot be assessed unless all patients underwent
radical prostatectomy to obtain whole mounted pathological correlates. In the
studied cohort only two patients proceeded to radical prostatectomy (patients
no 4 and 5 in table 30). The pathological assessment of these specimens
confirmed the presence of cancer in the area corresponding to the suspicious
lesion on MRI.
Another explanation is the presence of prostatitis. The inflammatory process
can lead to hypervascularity similar to that seen in cancers. This gives the
appearances of increased signal intensity on DCE-MRI mimicking a
malignant lesion. This was the case in 4 patients in this study, where DCE-
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MRI showed areas of increase contrast uptake, but biopsy of the suspicious
site confirmed inflammatory activity only.
The results of this study should be interpreted cautiously due to the small
sample size. The main limitation in this study that it was a pilot study which
only assessed tumour in the peripheral zones where the MRI appearance
and contrast uptake are characteristic. Central gland tumours were not
assessed because of the limitation of DCE-MRI in detecting cancer foci due
to the increased contrast uptake in the central gland secondary to benign
prostatic hyperplasia. However, central gland tumours are much less
common and biopsy of the central gland is not routinely performed.
It is unclear whether our diagnostic performance would improve the detection
of prostate cancer. In the three cases where cancer was found at the same
site of MR suspicious area, the rest of the 12 biopsies also detected cancer
within the same prostatic lobe. This means that the diagnosis of prostate
cancer will be made anyway regardless of the MRI findings and none of the
cancer would have been missed if TRUS biopsy had not been directed at the
abnormal areas detected by MRI.
6.5. Conclusion
My findings suggest that the role of DCE-MRI, in guiding TRUS biopsy in
patients with prior negative biopsy, is still in its infancy. To validate this
hypothesis, a larger number of patients must be studied and a better
registration of MRI and TRUS images should be performed.
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7. VISUALISATION OF PROSTATE CANCER FOCI AND
PROSTATE CAPSULE USING ENDORECTAL COIL
COMPARED TO PELVIC-PHASED ARRAY COIL AT 3
TESLA MRI
7.1. Introduction
The introduction of an endorectal coil (ERC) at 1.5T has improved the
visualization of the prostate and its surrounding structures due to an increase
in SNR. Hricak et al [170] reported superior staging results with the use of an
integrated endorectal and PPA coil compared with PPA coil alone (68% vs
77% accuracy rates). However reports have quoted variable results with
staging accuracy ranging from 60% to 80% for detecting extracapsular and
seminal vesicle infiltration [127, 169, 186-195]. When readers achieve high
specificity for extracapsular detection, their results suffer from considerable
reduction in sensitivity [169, 186, 190, 191], as well as considerable inter-
observer variability as discussed in chapter 3 [189, 191, 195]. The detection
rate of tumour foci within the gland using ERC imaging at 1.5T has been
reported to be 50-76% on T2w MR images with a false positive rate of 6-35%
[190, 193, 196].
Since 3 Tesla whole body MR scanning has come into clinical practice, its
image quality has been studied against endorectal coil at 1.5 Tesla imaging.
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Sosna et al [197] qualitatively compared the image quality of phased-array
body coil imaging of the prostate at 3Tesla with that of endorectal imaging at
1.5Tesla, and found them to be comparable.
It is a natural extension that the use of an ERC at 3T will further improve the
image quality by allowing higher spatial resolution to be implemented with
reduced slice thickness and smaller voxel size [100, 102]. This will potentially
lead to better visualization of the prostate gland and the surrounding
structures, revealing patho-anatomical details and subtle abnormalities not
seen on either external pelvic phased array (PPA) coil alone at 3T or the
combined external/endorectal coil at 1.5T [100, 198]. Preliminary results
comparing 3T endorectal MRI with whole mounted histopathology results
showed high staging accuracy mostly due to the improved detection of
minimal capsular invasion [102].
The aim of this study is to evaluate the impact of endorectal MRI at 3T on
visualisation of prostate zonal anatomy, identification of tumour extent and
delineation of the capsule and peri-prostatic soft tissue and seminal vesicles.
7.2. Methods
7.2.1.Patient characteristics
56 patients (median age of 67 years with a range of 51 to 85 years) with
biopsy proven prostate cancer were referred from the urology department for
endorectal MR imaging. Median PSA was 8.4 ng/mL (range from 0.7 to 250
ng/mL) and median Gleason grade was 7 (range from 5 to 9). Exclusion
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criteria were contraindications to MR imaging (e.g cardiac pacemakers, intra-
orbital metal foreign bodies), and contraindications to endorectal coil insertion
(e.g anorectal surgery, inflammatory bowel disease).
MR imaging was performed 3-4 weeks after prostate biopsy. The study
protocol was approved by the institutional ethics board. Patient preparation
was discussed in chapter 3.
7.2.2.MR technique
Endorectal and PPA MR imaging were performed with a 3T whole-body
scanner (Signa HDx, GE Healthcare, Milwaukee, USA). The examination
was performed with patients in the supine position. Bowel peristalsis was
suppressed with an intravenous injection of 20 mg of hyoscine-N-
butylbromide (Buscopan, Boehringer Ingelheim Limited) immediately before
the start of the examination. Initially, high resolution T2 weighted images
were obtained using an eight channel PPA coil (GE Healthcare). The
following sequences were obtained: three plane localiser, low resolution axial
T2w fast spin-echo (FSE) images, high resolution axial and coronal T2w FSE
to assess the prostate gland and surrounding structures (TR/TE: 3100/97.3
ms, slice thickness: 3.0 mm with no gap, matrix 384 x 256, field of view 20 x
20 cm, number of slices 26 over 6:50 mins). The surface coil was then
removed and a rigid ERC (Global Research Centre GRC, Münich, Germany)
was inserted with the patient in the lateral decubitus position, provided there
were no contraindications for its use. A three plane localiser was first
obtained to confirm coil position and to select locations for the axial images.
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Axial and coronal FSE T2w images were acquired (TR/TE: 5240/166.8 ms,
slice thickness: 2.5 mm, no inter-slice gap, matrix: 256 x 224, field of view 14
x 14 cm, number of slices 22 obtained over 3:35 mins).
7.2.3.MR image evaluation
All MR images were archived and analysed using an Advantage Windows
Workstation (GE Medical System) operating at 4.2-03 software level. MR
images were independently evaluated by two readers who had different
levels of experience in interpretation of MR findings. Reader A has more than
15 years of MR experience and reader B has one year of prostate MR
experience. ER coil and PPA coil images were rated for overall quality as
excellent, good, intermediate or poor (grade 1 to 4). The image quality was
considered to be excellent if it showed fine anatomical details and no
artefacts. It was considered to be poor if evaluation of the images was
difficult due to unclear anatomic delineation.
In identifying the anatomical details, we assessed the visibility (graded from
1-4) of the peripheral zones (PZ) and their delineation separate from the
central gland (CG) which implies both the transitional and central zones.
Allowance was made for the presence of tumour invading the surgical
capsule of the prostate and thus reducing differentiation of PZ and CG.
Hypointense areas on T2 weighted images were considered as suspicious of
prostate cancer. The degree of suspicion of the presence of malignancy
(graded from 1 = not seen, to 4 = highly suspicious) was assessed for both
ER and PPA images.
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Assessment of the prostatic capsule and the seminal vesicles was based on
five specific features described in the literature as highly indicative of
extracapsular extension (ECE) [127]. These features were discussed in
Chapter 3. The likelihood of extracapsular extension was rated using a 3-
point scale. A score of 1 indicated that extraprostatic disease was not
present; a score of 2, that ECE was possible due to minor capsular
irregularity and/or broad tumour contact; and a score of 3 indicated definite
ECE with unequivocal findings in the peri-prostatic soft tissues.
7.2.4.Statistical analysis
The data were analysed using the statistical software package SPSS for
Windows (version 13.0). Non parametric Sign test was used to determine if
there was a statistically significant difference between the number of times
the surface coil was rated superior to the ECR, versus the number of times
the ERC was rated superior.
Kappa statistics were used to measure the inter-observer level of agreement.
The following terms were used to describe the strength of agreement: ĸ = 0 -
0.20, poor agreement; ĸ= 0.21 – 0.40, fair agreement; ĸ= 0.41 – 0.60,
moderate agreement; ĸ= 0.61 – 0.80, substantial agreement; and ĸ= 0.81 –
1.00, near perfect agreement [128].
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7.3. Results:
The ERC was tolerated by all patients for the duration of the study which
amounted to 7 minutes. The presence of motion artefacts was significantly
higher using the ERC compared to surface coil (22 versus 11 cases); this
was mainly due to patient movement or rectal peristalsis. However, motion
artefact did not degrade the overall image quality which improved in 44%
(25/56) of cases (p< 0.001). [Tables 32 & 33].
Surface coil* ERC* P value
Discrimination
between PZ and CG
2.95 (0.81) 3.34 (0.69) <0.001
Visibility of PZ
2.84 (0.84) 3.34 (0.66) <0.001
Degree of tumour
identification
2.75 (1.10) 3.05 (0.96) 0.043
Overall image quality
2.96 (0.53) 3.30 (0.57) <0.001
Table 32. Visual assessment of image quality by reader A according to
specific criteria using PPA surface coil and ERC. (* Mean value of
assessment on a scale 1 to 4 quoted with SD in parentheses.)
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Surface coil* ERC* P value
Discrimination
between PZ and CG
2.89 (0.80) 3.32 (0.71) <0.001
Visibility of PZ 2.70 (0.80) 3.21 (0.82) <0.001
Degree of tumour
identification
2.77 (1.02) 2.96 (0.97) 0.132
Overall image quality 2.88 (0.63) 3.16 (0.75) 0.004
Table 33. Visual assessment of image quality by reader B according to
specific criteria using PPA surface coil and ERC. (* Mean value of
assessment on a scale 1 to 4 quoted with SD in parentheses.)
There was a moderate agreement between the two readers for discriminating
the PZ from the CG for both the PPA and ER coils (k= 0.49, p< 0.001 and k=
0.54, p< 0.001 respectively). Improvement in zonal discrimination was noted
in 23/56 (41%) of scans for reader A (p=0.001), and 24/56 (42%) for reader B
(p<0.001). [Table 34].
Reader A Reader B
Surface coil ERC Surface coil ERC
Poor 2 (3.6%) 1 (1.8%) 1 (1.8%) 1 (1.8%)
Moderate 14 (25%) 4 (7.1%) 15 (32.1%) 5 (8.9%)
Good 25 (44.6%0 26 (46.4%) 23 (41.1%) 25 (44.6%)
Excellent 15 (26.8%) 25 (44.6%) 14 (25%) 25 (44.6%)
Table 34. Discrimination between PZ and CG. Number and percentage
of patients in each category detailed for both readers.
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Figure 55. An example of PPA coil image (a) compared with ECR image
(b). Noticeable improvement in CG and PZ discrimination by using ERC.
PZ and CG discrimination using an ERC was unchanged in 29 cases for both
readers and worse in four and three cases for reader A and B respectively,
mainly due to motion and flare artefacts.
In assessing the visibility of the PZ, there was again a moderate agreement
between the two readers for both types of coils (PPA, k= 0.46, p< 0.001 and
ERC, k= 0.43, p< 0.001). The visibility of the PZ on T2w FSE imaging
improved in 53% (30/56) of patients for both readers (p< 0.001) [Table 35].
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Reader A Reader B
Surface coil ERC Surface coil ERC
Poor 3 (5.4%) 1 (1.8%) 5 (8.9%) 1 (1.8%)
Moderate 16 (28.6%) 3(5.4%) 14 (25%) 11 (19.6%)
Good 24 (42.9%) 28 (50%) 30 (53.6%) 19 (33.9%)
Excellent 13 (23.2%) 24 (42.9%) 7 (12.5%) 25 (44.6%)
Table 35. Visibility of PZ, the number and percentage of patients in each
category for both readers.
Figure 56. Better PZ visualization seen on ERC image (b) compared to
PPA coil image (a).
The visibility of the PZ was worse in only five patients [Table 35]. This was
due to significant movement artefact in four patients and coil malposition in
one further case.
There was a moderate agreement between the two readers for the
assessment of the degree of tumour identification on T2 weighted imaging
using both the surface coil and ERC (k= 0.53, p< 0.001 and k= 0.43, p<
0.001). Tumour foci were better identified using the ERC in 29% and 32% for
183
readers A & B respectively [Table 36]. However, this was not statistically
significant (p=0.52 p=0.78 for both readers).
Reader A Reader B
Surface coil ERC Surface coil ERC
Poor 12 (21.4%) 7 (12.5%) 9 (16.1%) 7 (12.5%)
Moderate 6 (10.7%) 3 (5.4%) 10 (17.9%) 6 (10.7%)
Good 22 (39.3%) 26 (46.4%) 22 (39.3%) 25 (44.6%)
Excellent 16 (28.6%) 20 (35.7%) 15 (26.8%) 18 (32.1%)
Table 36. Degree of tumour identification according to reader.
More importantly, the use of the ERC allowed the identification of eight
tumours by reader A and five tumours by reader B on T2w imaging which
were not visualized with a similar sequence using the PPA coil [Figure 57].
Figure 57. A 63 year old man with PSA of 8.0 and biopsy proven
prostate cancer with Gleason score of 7. T2 weighted image using PPA
(a) does not show any abnormalities. By using ERC (b) a low signal
intensity area is seen in the right PZ.
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Regarding staging of the disease [Table 37], there was a moderate
agreement between readers in identifying definite or possible extracapsular
extension (k=0.53, p<0.001), but near perfect agreement was achieved in
staging assessment using the ERC (k= 0.85, p<0.001).
ERC imaging
PPA
coil
Imaging
Organ-
confined
Possible
ECE
Definite
ECE Total
Organ-
confined 32/26 2/3 3/3 37/32
Possible
ECE 2/7 1/2 0/1 3/10
Definite
ECE 5/4 1/0 10/10 16/14
Total 39/37 4/5 13/14 56/56
Table 37. Extracapsular cancer extension as seen on T2w images
(comparison between surface coil and ER coil imaging for reader A /
reader B)
For the experienced reader, 37 cases showed an intact capsule on surface
coil imaging, but five of the 37 patients (13.5%) were upstaged to definite (3
cases) or suspicious (2 cases) extracapsular disease using the ER coil
[Figure 58].
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Figure 58. Low signal intensity area was seen in the left PZ and the
cancer was staged as T2 (organ confined) on PPA coil image (a). ERC
image shows the same low signal intensity area, causing irregularity of
the prostatic capsule (b) suspicious of extraprostatic cancer extension
(T3a).
On the other hand, five out of the sixteen patients (31%) who were thought to
have definite extracapsular extension on surface coil imaging, were down-
staged to organ confined disease after ERC imaging [Figure 48].
Figure 59. The prostatic capsule over the left PZ is not clearly seen
using PPA coil (a). A better identification of the capsule allowed the
reader to stage the disease as T2.
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A noticeable alteration in identification of capsular penetration was found in
the assessment by the less experienced reader B. There was a change in
capsular staging in 17 cases. Seven cases suspicious of ECE and four cases
of definite ECE were restaged as organ confined at ERC assessment. The
remaining six cases with T2 disease at PPA evaluation were upstaged to
either possible T3 (3 cases) or definite T3 (3 cases).
Readers A & B identified five and six cases respectively in which the
presence of neurovascular bundle involvement on surface coil imaging was
refuted using the ERC, due to better visualization of the recto-prostatic angle
(p=0.063, p=0.031 for readers A & B).
Seminal vesicle assessment likewise improved for readers with 6/15 and
3/11 of cases of suspected SVI (readers A & B respectively) on PPA coil
imaging, showing no significant abnormality on ERC imaging.
7.4. Discussion:
In this study, we evaluated T2 weighted MR images of the prostate looking at
the zonal anatomy, cancer foci, prostatic capsule and the relationship of
structures to each other, as well as to the neurovascular bundles and seminal
vesicles, based on the spatial resolution and tissue contrast achievable at 3
T.
Previous studies have addressed the superiority of ERC MR imaging with
regards to visualization of tumour foci and staging of the disease. Bloch et al
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addressed the higher spatial resolution achieved at 3 T ERC and the
reduction in voxel size to 0.35 mm3 [100]. This allows an excellent
visualization of anatomic details such as seminal ducts, intraprostatic urethra,
pseudocapsule and small blood vessels. Heijmink et al [199] also achieved
an improvement in spatial resolution and image quality, and substantial
decrease in voxel size when ERC was used compared with PPA coil (0.16
mm3 vs 0.73 mm3 ).
In my study voxel sizes of 1.21 mm3 and 0.84 mm3 were achieved using PPA
and ERC respectively. These relatively high voxel sizes, compared to
previous reports, were due to low matrix size and large FOV with the
advantage of reduction in scanning time and minimizing patient discomfort.
Better discrimination between the PZ and CG often lead to better
identification of tumours that originate from the PZ and invade into the CG.
The stromal layer which separates the PZ from the transitional zone seems
to have a role as a barrier against tumour extension, keeping it confined to
the zone in which it originated. However, 23% of prostate cancers involve
both zones [200]. Identifying this stromal layer on MR imaging, can help in
localising the tumour foci. This can be an additional advantage to guide
modern focal ablation techniques, especially in cases where prostatic
hypertrophy is present. Our study showed a 41% improvement in identifying
the stromal layer and discriminating the PZ and CG when we used the ERC
compared to surface coil T2w imaging. This improvement was noted
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especially in the presence of CG hypertrophy which is common in this cohort
of patients.
Better visibility of the PZ allows more accurate tumour identification for
further analysis. This includes tumour volume measurement as well as
comparing and registering data with other MR parameters such as dynamic
contrast-enhanced and diffusion weighted imaging. In this study ERC
imaging has more clearly delineated PZ tumour foci in 53% of cases, with
better tumour identification in 29% and 32% for readers A and B respectively.
Therefore, it is reasonable to say that ERC MR imaging should be an
important component to prostate MRI for localisation and characterization of
tumour foci.
With regards to capsule assessment and extra-prostatic tumour extension,
this study demonstrated an alteration in staging (secondary to capsular
tumour penetration, involvement of neurovascular bundles and seminal
vesicle) in 12 and 18 cases for the experienced and less experienced
readers respectively. These changes in staging can affect patients’
management. Prostate cancer was down-staged on ERC MRI in 7 and 13
cases for readers A and B respectively, allowing potentially curative
treatments such as surgery, brachytherapy or radiotherapy to be discussed
with the patient. On the other hand upstaging the disease on ERC imaging (5
cases for both readers) would prompt discussion of alternative/ additional
treatments such as hormonal or radio-therapy. In our centre patients with
possible extracapsular extension (possible T3) on MRI, who are suitable for
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radical prostatectomy, do proceed to surgery with a nerve scarifying
procedure and regional lymphadenectomy at the side of suspected
extracapsular extension. Adjuvant treatment is discussed following the
pathology result.
ERC imaging is not without pitfalls as images can suffer from increased
artefacts which can be due to different causes:
1) Signal shading, so a bright “flare” occurs in the posterior peripheral
zones due to the proximity of the coil to the gland, and signal
decreases in the anterior part of the gland [201]. Images can be
corrected using a series of proton-density weighted (PD) images
which can be noise filtered to demonstrate the sensitivity profile of the
coil. Using this information T2-weighted images acquired in the same
plane can be corrected for shading artefact [201]. This flare correction
improves image uniformity and visualization of prostatic anatomy.
2) Good image quality, as well as flare correction, is only possible when
there is no patient movement during the acquired sequence and
between T2 weighted and PD sequences. Motion can be due to
patient movement or rectal peristalsis. All patients received hyoscine-
N-butylbromide intravenously to reduce bowel peristalsis and therefore
reduce rectal motion artefact. When motion artefact was due to patient
movement, the affected sequence was repeated for optimal results (in
4 cases).
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3) Incorrect placement of the coil (ERC not parallel to the transverse
plane of the gland). In this study I inflated the balloon with 60 ml of air
to secure the coil in position following insertion, as well as applying
gentle traction to the balloon during inflation to prevent coil migration.
Although significantly more artefacts were present at ERC MR imaging
compared with PPA imaging at 3T (39% vs 19%), all other quality
characteristics improved with ERC imaging.
7.5. Conclusion:
The use of ERC at 3T significantly improves the image quality and
visualization of prostatic anatomical details which allow better identification of
tumour foci. This Improvement in localisation and staging needs to be further
evaluated against whole mounted pathology specimens.
We found that the patients who benefit most from the use of an ERC are
those who are suitable for radical prostatectomy and who require optimal
staging accuracy and those who are considered for focal treatments such as
HIFU, photodynamic therapy or cryotherapy.
Future advances in MR technology such as 16 or 32 channels PPA coil may
enhance spatial resolution and improve prostatic anatomical and pathological
details. Until an improved surface coil is developed, patients who are referred
for pre-treatment tumour staging and localisation at 3T need to undergo ERC
imaging, either as a separate procedure or integrated with a PPA surface
coil.
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Chapter Eight
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8. FUTURE APPLICATIONS OF PROSTATE MRI
Advances in MRI protocols employing a multi-parametric approach have
succeeded in achieving reasonable accuracy for tumour localisation and
staging. This has led to the greater use of MRI in PCa management.
Moreover, recent studies demonstrated further utility of MRI in evaluating risk
stratification, predicting tumour aggressiveness and cancer survival, and
guiding interventions including prostate biopsy and ablation.
In this Chapter, I will discuss the potential future applications of prostate MRI
and address some of the recent studies.
8.1. Predicting tumour aggressiveness and
relation to Gleason score.
I have demonstrated in my research the differences in various MR
parameters between cancer lesions and normal peripheral zone. These
include ADC and DCE parameters. I have also shown a good correlation
between ADC and tumour cellularity. This relationship between tumour
features on MRI and histologic composition indicates a potential use of MRI
to serve as an additional prognostic marker in assessing cancer
aggressiveness and the need for treatment.
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In this Chapter, I explore the recent research correlating various MR
parameters with Gleason score, this being the most effective prognostic
factor for survival, biochemical progression and recurrence.
8.1.1. Correlation between Gleason score and ADC values
Various recent studies have reported a significant negative correlation
between Gleason score obtained from radical prostatectomy specimen and
ADC values [202-204]. Verma et al [203], studied 110 patients with prostate
cancer who underwent endorectal prostate MRI at 1.5 Tesla before radical
prostatectomy. The author reported the ADC value in a total of 197 tumours
to be negatively correlated with Gleason grades (r = -0.39). AT 3 Tesla
endorectal MRI, Vargas et al [202], studied 51 patients and found that a low
mean ADC value was significantly associated with a higher tumour Gleason
score (P = 0.017).
Despite the statistically significant negative correlation between ADC and
Gleason score, it was noted that there was considerable overlap in ADC
values between Gleason score groups (low, intermediate and high risk
groups), as well as variation of ADC values within the same group [204]. One
of the reasons for the overlap in ADC values is the heterogeneity of prostate
cancer and the presence of different Gleason grades within the same
prostate [204].
Therefore, although there is a strong correlation between ADC and Gleason
scores, it is currently insufficient for immediate diagnostic utility and further
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investigation is needed to facilitate the noninvasive assessment of cellular
density and thus Gleason score by the use of diffusion weighted imaging.
8.1.2. Assessment of cancer aggressiveness using spectroscopic
prostate MR Imaging.
MR spectroscopic prostate imaging provides spatial mapping of the levels of
various metabolites including citrate, choline and creatine in the prostate
gland. PCa lesions are characterised by lower citrate levels and/or higher
choline levels compared to normal tissue [205]. Therefore, the ratio of choline
and creatine to citrate can be used as a marker for PCa.
Kobus et al [206] in a retrospective study involving 72 patients with PCa,
validated the performance of spectroscopic MR imaging of the prostate at 3
Tesla with an endorectal coil. They assessed tumour aggressiveness based
on choline + creatine / citrate and choline / creatine ratios, using the Gleason
score from radical prostatectomy specimen as the gold standard. The author
reported a good separation of low grade from high grade tumours based on
the above measured parameters. The study also analysed the malignancy
rating using a standardized threshold approach and achieved an AUC of 0.78
in discrimination between different aggressive classes. This preliminary study
offers potential for noninvasive MR assessment of PCa aggressiveness.
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Further confirmation of the above conclusion needs to be addressed in larger
studies, including assessment of tumour arising in the central gland as well
as in peripheral zones.
8.1.3. Assessment of cancer aggressiveness using DCE-MR
Imaging
Although there is good evidence that DCE-MRI parameters reflect
angiogenesis and can discriminate between cancerous lesions and normal
peripheral zone, up to date, there is no published data to suggest that DCE-
MR parameters correlate with Gleason score or tumour aggressiveness.
Previous studies [207, 208] examining the correlation between DCE-MRI
parameters and various pathological features failed to show a correlation
between tumour vascular permeability or maximum tumour gadolinium
concentration and Gleason score or PSA.
However, recent MR studies on rectal tumours showed significant difference
for Ktrans with Duke’s staging with moderate and promising correlation with
TNM staging [209]. This implies that further in vivo DCE-MRI studies on
organs with cancerous involvement are needed to address this issue. Future
research should study the correlation between various DCE-MRI parameters
and microvessel density which can be counted using various
immunohistochemistry techniques including CD31 expression. The higher the
microvessel density count, the more likely the tumour is to be aggressive with
a greater risk of metastasis.
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8.2. The role of prostate MRI in treatment
selection for organ confined prostate
cancer.
Various nomograms are available that combine clinical and biopsy findings to
predict the probability of organ confined disease, classifying risks of prostate
cancer, or predicting biochemical recurrence-free survival following surgery.
With the advances of MRI as a noninvasive diagnostic imaging tool, recent
studies have looked at incrementing the value of MRI in pre-operative
nomograms. Wang et al [210], performed a retrospective study assessing
data from 573 men with PCa who underwent pre-operative endorectal MRI
and radical retropubic prostatectomy with pelvic lymphadenectomy. The
Kattan pre-operative nomogram was used to estimate the risk of seminal
vesicle involvement (SVI). The author found that the addition of endorectal
MRI to the Kattan nomogram resulted in a valuable incremental improvement
in its prediction for SVI. The area under the receiver operating characteristic
curve was markedly greater for endorectal MRI plus the Kattan nomogram
(0.87) than for either technique alone (0.80 and 0.76 for nomogram and MRI
only respectively).
Other researchers developed tools using combined MRI variables, PSA level,
and Gleason sum to predict 5 year biochemical recurrence after radical
prostatectomy [211]. The authors found that the area under ROC of their new
nomogram including MRI data was significantly greater than these of other
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predictive tools including Kattan’s nomogram (0.897 versus 0.737
respectively).
Shuckla-Dave et al [212] looked at incorporating MR imaging and
spectroscopy in pre-operative nomogram for the prediction of insignificant
prostate cancer. The probability of insignificant PCa on MRI/MRSI was
recorded prospectively by two radiologists on a scale from 0 (definitely
insignificant) to 3 (definitely significant PCa). Insignificant PCa was then
defined on surgical pathology. The author concluded that MR models
performed significantly better than the base clinical model (without biopsy
data), and similar to a comprehensive clinical tool (with biopsy data). The
authors also designed new nomogram models incorporating MRI results and
clinical data without the need for detailed biopsy data.
Further research is needed to evaluate whether patients with insignificant
cancer who have opted to have active surveillance should undergo annual
MRI as part of their predictive tool for assessment of aggressiveness and risk
of progression. In a recent review article, Ouzzane et al [213] summarised
the role of MRI in the selection and monitoring of patients on active
surveillance. The authors concluded that incorporation of MRI data into active
surveillance selection criteria for patients with low-risk CaP provides a better
baseline prognostic evaluation compared to the use of the clinical and
histologic data only. This can reduce the number of patients reclassified as
higher risk at subsequent follow-up biopsies. The routine application of MRI
in decision making in this group of patients requires highly skilled MR
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radiologists and advanced MRI technology and should be weighed against
cost to justify its use.
8.3. MRI guided prostate biopsy
As mentioned in Chapter 6, the detection rate of prostate cancer in men with
elevated and/or rising prostate specific antigen levels after negative TRUS
biopsy is relatively poor. Targeting the suspicious areas on MRI, using USS,
presents a significant problem with registering the two imaging modalities.
Therefore, there is a strong present need for MRI-guided prostate biopsy as
a tool to enhance detection rate, especially when multi-parametric MRI has
considerable capability in finding cancerous lesions in the prostate.
Few recent studies have looked into the feasibility of performing real time MR
guided prostate biopsy (MRGB). Beyersdorff et al [214] were the first to
describe transrectal MRGB in a closed MR system by using anatomical T2-
weighted MR images as part of a pre-biopsy planning. Hambrock et al [215]
tested the feasibility of directing MR-guided biopsies by translating maps of
suspicious areas of tumour in the prostate, identified from multiparametric 3T
MRI data (including T2W MRI, DWI, and DCE-MRI), onto T2w MR images.
This was performed using a 32-channel coil on a 3 Tesla MRI scanner.
Results were analysed from 21 patients with elevated PSA levels and
negative previous USS guided biopsy results. Tumour suspicious regions
were identified, successfully translated on to T2w MR images and biopsied
under MR guidance. 95% of patients had identifiable pathology using this
technique.
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In another study by the same group [216], the author analyzed the results of
68 patients who underwent multi-parametric 3T MR-guided biopsy and
compared them with results from a matched population of patients who
underwent multi-session TRUS-guided biopsy. The tumour detection rate for
MR-guided biopsy was 59% using a median of four cores, which was
significantly higher than that of TRUS-guided prostate biopsy (17%).
Krieger et al [217] described in detail the technique of MR-guided prostate
biopsy including patient positioning, approach, guiding and tracking
instruments, and the experiments in manual and robotic techniques. The
transrectal approach was described by Futterer et al [218] as the preferable
one, as it requires minimal anaesthetic and provides the shortest way to
reach the prostate therefore reducing the potential for needle deflection.
Other feasible approaches such as transperineal and transgluteal were also
described [217].
The description of the procedure by the above authors can be summarised
as follows:
 Patient position can be prone or supine depending on the device used.
A needle guide filled with gadolinium is inserted rectally and the
patient is positioned in the scanner bore with the pelvic phased array
coil in place. Then multi-sequence MRI is performed with DWI, DCE
and T2 weighted imaging to identify the region of interest (the
suspicious prostatic area). These images are then translated to a T2 w
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image using anatomical landmarks and 3 dimensional position
estimation.
 The needle guide then can be advanced into the suspected lesion and
biopsies are performed using an MR compatible biopsy gun. The
procedure time is about 35 minutes.
In summary, MR-guided biopsies of the prostate are becoming more and
more available. Both robotic and manual techniques have comparable results
regarding accuracy and speed [219]. Although there is currently no
consensus on the optimal technique, there is growing evidence that the use
of MR-guided biopsy is highly useful in patient with high/ rising PSA but
negative USS-guided biopsies, and widespread practice should be
encouraged.
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8.4. Summary
I believe that prostate MRI, using a high magnetic field with a multi
sequences technique, has flourished in its role in prostate cancer diagnosis,
management and prognostication.
In this research, each study was described in a separate chapter and had
different cohort of patients. These were analysed in different time scale
during the 2 ½ years of the research. Although there was some overlap of
patient cohorts between each chapter and some patients’ MR data were
used in more than one study.
I have shown in my thesis that prostate MRI can achieve a diagnostic
localisation accuracy of 80% using dynamic contrast enhancement, with a
sensitivity of 79% and a specificity of 83%. The detection rate is particularly
good in the peripheral zones where sensitivity reaches 90% and specificity
71%.
MRI also demonstrates high accuracy rate for prostate cancer staging
especially with the use of an endorectal coil with an area under ROC curve of
0.93 given a sensitivity of 67% and specificity of 96%. There is leaning
towards high specificity at the expense of moderate sensitivity to prevent
overstaging of the disease, which may lead to potentially curative surgical
treatment being withheld on the basis of false positive MR imaging.
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These high accuracy rates using endorectal coil is mainly due to better
tumour visualisation and identification, as in this study, the MR visibility of the
PZ improved in 53% of cases following the use of ERC. Furthermore, the
tumour foci were better identified in 29% of cases.
The above results cannot be achieved without an experienced radiologist
who has completed a learning curve. I have demonstrated the difference in
staging and localisation results between readers depending on their level of
MR experience. The performance of the less experienced reader is greatly
improved with the use of DCE-MRI and ERC compared with T2 weighted
imaging alone.
In addition to the localisation and staging performance, I demonstrated in this
study the role of MRI as a biomarker for prostate cancer. Based on diffusion
weighted imaging, the ADC values were significantly lower (p < 0.001) in
regions pathologically determined to be tumour (1.45±0.26 x10-3 mm2/s)
compared to regions assigned as normal peripheral zone tissue (1.90±0.33
x10-3 mm2/s). The ADC correlates significantly with cell density (r = -0.50, p <
0.0001), leading to the belief that calculating ADC may reflect tumour
aggressiveness as the average cell density is significantly higher in malignant
tissues than normal prostatic tissues.
Moreover, DCE-MRI has also revealed significant separation between
malignant and normal tissues based on enhancement parameters. I have
produced enhancement data which has shown that malignant prostatic
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lesions have a 56% higher MaxEI compared to normal PZ and take nearly
half the time to reach that maximum. Similarly, the wash-in rate as
represented by the initial slope was much higher in cancer lesions compared
to normal PZ. As contrast enhancement is related to tumour angiogenesis,
increased and rapid enhancement may be related to more aggressive
tumour. However, this needs to be evaluated further in future studies.
In conclusion, I believe that this research has shone a light on the important
role of MRI in prostate cancer management and the huge potential for further
studies to enhance its role and benefit.
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